<!DOCTYPE html>
<html lang="en" xmlns:og="http://ogp.me/ns#" xmlns:fb="https://www.facebook.com/2008/fbml">
    <head>
        <meta charset="utf-8">
        <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
        <title>Molecules  | Free Full-Text | Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors | HTML</title><link rel="stylesheet" href="http://img.mdpi.org/assets/css/jquery-ui-1.10.4.custom.min.css?63fcc31cab108f00">
        <link rel="stylesheet" href="http://img.mdpi.org/assets/css/font-awesome.min.css?feda974a77ea5783">
        <link rel="stylesheet" href="http://img.mdpi.org/assets/css/main.css?7de3785de19c3740">
        <link rel="shortcut icon" href="http://img.mdpi.org/favicon.ico?2cc1a03f42824a2d">
                            <link rel="stylesheet" media="all" type="text/css" href="/journal/molecules/css">
        <link rel="stylesheet" href="http://img.mdpi.org/assets/css/article-html.css?ba9b57c88b775ff7">
    <meta name="title" content="Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors">
	<meta name="description" content="The geometries and energies of factor Xa inhibitors edoxaban, eribaxaban, fidexaban, darexaban, letaxaban, and the dual factor Xa and thrombin inhibitors tanogitran and SAR107375 in both the gas-phase and aqueous solution were studied using the Becke3LYP/6-31++G(d,p) or Grimme’s B97D/6-31++G(d,p) method. The fully optimized conformers of these anticoagulants show a characteristic l-shape structure, and the water had a remarkable effect on the equilibrium geometry. According to the calculated pKa values eribaxaban and letaxaban are in neutral undissociated form at pH 7.4, while fidexaban and tanogitran exist as zwitterionic structures. The lipophilicity of the inhibitors studied lies within a large range of log P between 1 and 4. The dual inhibitor SAR107375 represents an improvement in structural, physicochemical and pharmacokinetic characteristics over tanogitran. At blood pH, SAR107375 predominantly exists in neutral form. In contrast with tanogitran, it is better absorbed and more lipophilic and active after oral application." >
	<link rel="image_src" href="http://img.mdpi.org/img/journals/molecules-logo.png?97552ead561a93b2" >
	<meta name="dc.title" content="Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors">

            <meta name="dc.creator" content="Milan Remko">
            <meta name="dc.creator" content="Anna Remková">
            <meta name="dc.creator" content="Ria Broer">
    
    <meta name="dc.type" content="Article">
    <meta name="dc.source" content="Molecules 2016, Vol. 21, Page 185">
    <meta name="dc.date" content="2016-02-04">
            <meta name ="dc.identifier" content="10.3390/molecules21020185">
    
    <meta name="dc.publisher" content="Multidisciplinary Digital Publishing Institute">
    <meta name="dc.rights" content="http://creativecommons.org/licenses/by/3.0/">
    <meta name="dc.format" content="application/pdf" >
    <meta name="dc.language" content="en" >
	<meta name="dc.description" content="The geometries and energies of factor Xa inhibitors edoxaban, eribaxaban, fidexaban, darexaban, letaxaban, and the dual factor Xa and thrombin inhibitors tanogitran and SAR107375 in both the gas-phase and aqueous solution were studied using the Becke3LYP/6-31++G(d,p) or Grimme’s B97D/6-31++G(d,p) method. The fully optimized conformers of these anticoagulants show a characteristic l-shape structure, and the water had a remarkable effect on the equilibrium geometry. According to the calculated pKa values eribaxaban and letaxaban are in neutral undissociated form at pH 7.4, while fidexaban and tanogitran exist as zwitterionic structures. The lipophilicity of the inhibitors studied lies within a large range of log P between 1 and 4. The dual inhibitor SAR107375 represents an improvement in structural, physicochemical and pharmacokinetic characteristics over tanogitran. At blood pH, SAR107375 predominantly exists in neutral form. In contrast with tanogitran, it is better absorbed and more lipophilic and active after oral application." >

            <meta name="dc.subject" content="density functional theory (DFT)" >
            <meta name="dc.subject" content="anticoagulants" >
            <meta name="dc.subject" content="conformation" >
            <meta name="dc.subject" content="solvent effect" >
            <meta name="dc.subject" content="acidity" >
            <meta name="dc.subject" content="lipophilicity" >
            <meta name="dc.subject" content="absorption" >
    
    <meta name ="prism.publicationName" content="Molecules">
    <meta name ="prism.publicationDate" content="2016-02-04">
    <meta name ="prism.volume" content="21">
    <meta name ="prism.number" content="2">
    <meta name ="prism.section" content="Article" >
    <meta name ="prism.startingPage" content="185" >

    
    <meta name="citation_journal_title" content="Molecules">
    <meta name="citation_publisher" content="Multidisciplinary Digital Publishing Institute">
    <meta name="citation_authors" content="Remko, Milan ; Remková, Anna ; Broer, Ria ">
    <meta name="citation_title" content="Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors">
    <meta name="citation_date" content="2016-02-04">
    <meta name="citation_volume" content="21">
    <meta name="citation_issue" content="2">
    <meta name="citation_firstpage" content="185">

    
            <meta name="citation_doi" content="10.3390/molecules21020185">
    
    <meta name="citation_id" content="mdpi-molecules21020185">
    <meta name="citation_abstract_html_url" content="http://www.mdpi.com/1420-3049/21/2/185">
            <meta name="citation_pdf_url" content="http://www.mdpi.com/1420-3049/21/2/185/pdf">
        <link rel="alternate" type="application/pdf" title="PDF Full-Text" href="http://www.mdpi.com/1420-3049/21/2/185/pdf">
        <meta name="fulltext_pdf" content="http://www.mdpi.com/1420-3049/21/2/185/pdf">
                <meta name="citation_fulltext_html_url" content="http://www.mdpi.com/1420-3049/21/2/185/htm">
        <link rel="alternate" type="text/html" title="HTML Full-Text" href="http://www.mdpi.com/1420-3049/21/2/185/htm">
        <meta name="fulltext_html" content="http://www.mdpi.com/1420-3049/21/2/185/htm">
                <link rel="alternate" type="text/xml" title="XML Full-Text" href="http://www.mdpi.com/1420-3049/21/2/185/xml">
        <meta name="fulltext_xml" content="http://www.mdpi.com/1420-3049/21/2/185/xml">
    <meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@MDPIOpenAccess" /><meta name="twitter:image" content="http://img.mdpi.org/img/journals/molecules-logo-sq.png?97552ead561a93b2" /><meta property="fb:app_id" content="131189377574"/><meta property="og:site_name" content="MDPI"/>
 	<meta property="og:type" content="article"/>
 	<meta property="article:publisher" content="https://www.facebook.com/MDPIOpenAccessPublishing"/>
 	<meta property="og:url" content="http://www.mdpi.com/1420-3049/21/2/185" />
 	<meta property="og:title" content="Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors" />
	<meta property="og:description" content="The geometries and energies of factor Xa inhibitors edoxaban, eribaxaban, fidexaban, darexaban, letaxaban, and the dual factor Xa and thrombin inhibitors tanogitran and SAR107375 in both the gas-phase and aqueous solution were studied using the Becke3LYP/6-31++G(d,p) or Grimme’s B97D/6-31++G(d,p) method. The fully optimized conformers of these anticoagulants show a characteristic l-shape structure, and the water had a remarkable effect on the equilibrium geometry. According to the calculated pKa values eribaxaban and letaxaban are in neutral undissociated form at pH 7.4, while fidexaban and tanogitran exist as zwitterionic structures. The lipophilicity of the inhibitors studied lies within a large range of log P between 1 and 4. The dual inhibitor SAR107375 represents an improvement in structural, physicochemical and pharmacokinetic characteristics over tanogitran. At blood pH, SAR107375 predominantly exists in neutral form. In contrast with tanogitran, it is better absorbed and more lipophilic and active after oral application." /><meta property="og:image" content="http://img.mdpi.org/img/journals/molecules-logo-sq.png?97552ead561a93b2" />





                <link rel="alternate" type="application/rss+xml" title="MDPI Publishing - Latest articles" href="http://www.mdpi.com/rss">
        		  <script type="text/x-mathjax-config">
    MathJax.Hub.processSectionDelay = 0;
      MathJax.Hub.Config({
        menuSettings: {
          CHTMLpreview: false
        },
        "CHTML-preview":{
          disabled: true
        },
        "HTML-CSS": {
          availableFonts: ["TeX"],
          preferredFonts: "TeX",
          webFont:"TeX",
          imageFont:"TeX",
          undefinedFamily:"'Arial Unicode MS',serif"
        },
        "TeX": {
          extensions: ["noErrors.js"],
          noErrors: {
            inlineDelimiters: ["",""],
            multiLine: true,
            style: {
              "font-size":   "90%",
              "text-align":  "left",
              "color":       "black",
              "padding":     "1px 3px",
              "border":      "1px solid"
            }
          }
        }
      });
    </script>

    <script type="text/javascript" src="http://img.mdpi.org/bundles/mathjax/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
        <meta name="google-site-verification" content="PxTlsg7z2S00aHroktQd57fxygEjMiNHydKn3txhvwY">
        <!--[if lt IE 9]>
        <script src="//html5shiv.googlecode.com/svn/trunk/html5.js"></script>
        <![endif]-->

    </head>
    <body>
    			  							

		<div class="direction direction_right" id="small_right" style="border-right-width: 0px; padding:0;"><i class="fa fa-caret-right fa-2x" style="float: right; margin: 27px 5px 0px 0px"></i></div>
	<div class="big_direction direction_right" id="big_right" style="border-right-width: 0px;  padding: 0 0 0 1em;">
		<i class="fa fa-caret-right fa-2x" style="margin: 27px 5px 0px 0px; float:right"></i>
		<div style="text-align: right; position:relative; margin: 0 1.7em 0 0">
									Next Article in Journal<br>
				<div><a href="http://www.mdpi.com/1420-3049/21/2/194">Cellular Uptake and Photo-Cytotoxicity of a Gadolinium(III)-DOTA-Naphthalimide Complex “Clicked” to a Lipidated Tat Peptide</a></div>
					 		 		 	</div>
	</div>
	
		<div class="direction" id="small_left" style="border-left-width: 0px"><i class="fa fa-caret-left fa-2x" style="margin: 27px 4px;"></i></div>
	<div class="big_direction" id="big_left" style="border-left-width: 0px;">
		<i class="fa fa-caret-left fa-2x" style="float: left; margin: 27px 4px"></i>
		<div>
									Previous Article in Journal<br>
				<div><a href="http://www.mdpi.com/1420-3049/21/2/174">Antioxidant and DNA Damage Protecting Activity of Exopolysaccharides from the Endophytic Bacterium <i>Bacillus cereus</i> SZ1</a></div>
					 			 	 	</div>
	</div>
		<div style="clear: both;"/>
        <div id="container">
            <div id="stripeleft" style="background:url(http://img.mdpi.org/img/design/stripe_left.png?7a19bc8a135e08fa) no-repeat top left">
                <div id="striperight" style="background:url(http://img.mdpi.org/img/design/stripe_right.png?a2355fb262ff8e6e) no-repeat top right">
                    <div id="topmenu" style="padding:0;">
                    <div id="topmenu_container" style="padding-top:9px;">
                            <ul style="padding:0 1.5em;" class="subMenu">
                                <li class="user-quick-cmd">
                                                                            <a href="http://susy.mdpi.com/user/manuscripts/upload?journal=molecules">Submit to Molecules</a>
                                                                            <a href="/user/login">Login</a>
                                        <a href="/user/register">Register</a>
                                                                    </li>
                                <li><a href="/">MDPI</a></li>
                                <li><a href="/about/journals">Journals A-Z</a></li>
                                <li><a href="/guidelines">Information & Guidelines</a>
							    	<ul>
							        	<li><a href="/authors">For Authors</a></li>
							        	<li><a href="/reviewers">For Reviewers</a></li>
		                                <li><a href="/editors">For Editors</a></li>
		                                <li><a href="/librarians">For Librarians</a></li>
		                                <li><a href="/xml">For Publishers</a></li>
		                                <li><a href="/about/openaccess">Open Access Policy</a></li>
							        </ul>
							    </li>
                                <li><a href="/about">About</a></li>
                                <li><a href="/editorial_process">Editorial Process</a></li>
                                                            </ul>
                            </div>
                    </div><div id="search">
                    	<table class="container" cellspacing="0" cellpadding="0">
                            <tr>
                                <td class="logo">
                                    <a href="/journal/molecules"><img src="http://img.mdpi.org/img/journals/molecules-logo.png?97552ead561a93b2" alt="molecules-logo" title="molecules Open Access Journals" style="max-height:70px; max-width:220px;"></a>
                                </td>
								
																																	
                                <td class="form"><!-- search form -->
    <form  action="/search" method="get" id="searchBar">
      <table>
        <tr><td>
        <table class="search_form" cellspacing="0" cellpadding="2">
            <tr>
                <td><div class="lb">Title / Keyword</div></td>
                <td class="field"><input type="text" id="q" tabindex="1" name="q" value="" /></td>
                <td><div class="lb">Journal</div></td>
                <td class="field"><select id="journal" tabindex="4" name="journal">
                        <option value="">all</option>
                         
                            <option value="actuators">Actuators</option>
                         
                            <option value="admsci">Administrative Sciences</option>
                         
                            <option value="aerospace">Aerospace</option>
                         
                            <option value="agriculture">Agriculture</option>
                         
                            <option value="agronomy">Agronomy</option>
                         
                            <option value="algorithms">Algorithms</option>
                         
                            <option value="animals">Animals</option>
                         
                            <option value="antibiotics">Antibiotics</option>
                         
                            <option value="antibodies">Antibodies</option>
                         
                            <option value="antioxidants">Antioxidants</option>
                         
                            <option value="applsci">Applied Sciences</option>
                         
                            <option value="arts">Arts</option>
                         
                            <option value="atmosphere">Atmosphere</option>
                         
                            <option value="atoms">Atoms</option>
                         
                            <option value="axioms">Axioms</option>
                         
                            <option value="batteries">Batteries</option>
                         
                            <option value="behavsci">Behavioral Sciences</option>
                         
                            <option value="beverages">Beverages</option>
                         
                            <option value="bioengineering">Bioengineering</option>
                         
                            <option value="biology">Biology</option>
                         
                            <option value="biomedicines">Biomedicines</option>
                         
                            <option value="biomimetics">Biomimetics</option>
                         
                            <option value="biomolecules">Biomolecules</option>
                         
                            <option value="biosensors">Biosensors</option>
                         
                            <option value="brainsci">Brain Sciences</option>
                         
                            <option value="buildings">Buildings</option>
                         
                            <option value="carbon">C</option>
                         
                            <option value="cancers">Cancers</option>
                         
                            <option value="catalysts">Catalysts</option>
                         
                            <option value="cells">Cells</option>
                         
                            <option value="challenges">Challenges</option>
                         
                            <option value="chemosensors">Chemosensors</option>
                         
                            <option value="children">Children</option>
                         
                            <option value="chromatography">Chromatography</option>
                         
                            <option value="climate">Climate</option>
                         
                            <option value="coatings">Coatings</option>
                         
                            <option value="computation">Computation</option>
                         
                            <option value="computers">Computers</option>
                         
                            <option value="condensedmatter">Condensed Matter</option>
                         
                            <option value="cosmetics">Cosmetics</option>
                         
                            <option value="cryptography">Cryptography</option>
                         
                            <option value="crystals">Crystals</option>
                         
                            <option value="data">Data</option>
                         
                            <option value="dentistry">Dentistry Journal</option>
                         
                            <option value="diagnostics">Diagnostics</option>
                         
                            <option value="diseases">Diseases</option>
                         
                            <option value="diversity">Diversity</option>
                         
                            <option value="econometrics">Econometrics</option>
                         
                            <option value="economies">Economies</option>
                         
                            <option value="education">Education Sciences</option>
                         
                            <option value="electronics">Electronics</option>
                         
                            <option value="energies">Energies</option>
                         
                            <option value="entropy">Entropy</option>
                         
                            <option value="environments">Environments</option>
                         
                            <option value="epigenomes">Epigenomes</option>
                         
                            <option value="fermentation">Fermentation</option>
                         
                            <option value="fibers">Fibers</option>
                         
                            <option value="fishes">Fishes</option>
                         
                            <option value="fluids">Fluids</option>
                         
                            <option value="foods">Foods</option>
                         
                            <option value="forests">Forests</option>
                         
                            <option value="futureinternet">Future Internet</option>
                         
                            <option value="galaxies">Galaxies</option>
                         
                            <option value="games">Games</option>
                         
                            <option value="gels">Gels</option>
                         
                            <option value="genealogy">Genealogy</option>
                         
                            <option value="genes">Genes</option>
                         
                            <option value="geosciences">Geosciences</option>
                         
                            <option value="geriatrics">Geriatrics</option>
                         
                            <option value="healthcare">Healthcare</option>
                         
                            <option value="horticulturae">Horticulturae</option>
                         
                            <option value="humanities">Humanities</option>
                         
                            <option value="hydrology">Hydrology</option>
                         
                            <option value="informatics">Informatics</option>
                         
                            <option value="information">Information</option>
                         
                            <option value="infrastructures">Infrastructures</option>
                         
                            <option value="inorganics">Inorganics</option>
                         
                            <option value="insects">Insects</option>
                         
                            <option value="ijerph">IJERPH</option>
                         
                            <option value="ijfs">IJFS</option>
                         
                            <option value="ijms">IJMS</option>
                         
                            <option value="neonatalscreening">IJNS</option>
                         
                            <option value="inventions">Inventions</option>
                         
                            <option value="ijgi">IJGI</option>
                         
                            <option value="jcdd">JCDD</option>
                         
                            <option value="jcm">JCM</option>
                         
                            <option value="jdb">JDB</option>
                         
                            <option value="jfb">JFB</option>
                         
                            <option value="jfmk">JFMK</option>
                         
                            <option value="jof">JoF</option>
                         
                            <option value="jimaging">J. Imaging</option>
                         
                            <option value="jintelligence">J. Intell.</option>
                         
                            <option value="jlpea">JLPEA</option>
                         
                            <option value="jmse">JMSE</option>
                         
                            <option value="jpm">JPM</option>
                         
                            <option value="jrfm">JRFM</option>
                         
                            <option value="jsan">JSAN</option>
                         
                            <option value="land">Land</option>
                         
                            <option value="languages">Languages</option>
                         
                            <option value="laws">Laws</option>
                         
                            <option value="life">Life</option>
                         
                            <option value="lubricants">Lubricants</option>
                         
                            <option value="machines">Machines</option>
                         
                            <option value="magnetochemistry">Magnetochemistry</option>
                         
                            <option value="marinedrugs">Marine Drugs</option>
                         
                            <option value="materials">Materials</option>
                         
                            <option value="mca">MCA</option>
                         
                            <option value="mathematics">Mathematics</option>
                         
                            <option value="medsci">Medical Sciences</option>
                         
                            <option value="medicines">Medicines</option>
                         
                            <option value="membranes">Membranes</option>
                         
                            <option value="metabolites">Metabolites</option>
                         
                            <option value="metals">Metals</option>
                         
                            <option value="microarrays">Microarrays</option>
                         
                            <option value="micromachines">Micromachines</option>
                         
                            <option value="microorganisms">Microorganisms</option>
                         
                            <option value="minerals">Minerals</option>
                         
                            <option value="molbank">Molbank</option>
                         
                            <option value="molecules" selected="selected">Molecules</option>
                         
                            <option value="mti">MTI</option>
                         
                            <option value="nanomaterials">Nanomaterials</option>
                         
                            <option value="ncrna">ncRNA</option>
                         
                            <option value="nutrients">Nutrients</option>
                         
                            <option value="pathogens">Pathogens</option>
                         
                            <option value="pharmaceuticals">Pharmaceuticals</option>
                         
                            <option value="pharmaceutics">Pharmaceutics</option>
                         
                            <option value="pharmacy">Pharmacy</option>
                         
                            <option value="philosophies">Philosophies</option>
                         
                            <option value="photonics">Photonics</option>
                         
                            <option value="plants">Plants</option>
                         
                            <option value="polymers">Polymers</option>
                         
                            <option value="processes">Processes</option>
                         
                            <option value="proteomes">Proteomes</option>
                         
                            <option value="publications">Publications</option>
                         
                            <option value="recycling">Recycling</option>
                         
                            <option value="religions">Religions</option>
                         
                            <option value="remotesensing">Remote Sensing</option>
                         
                            <option value="resources">Resources</option>
                         
                            <option value="risks">Risks</option>
                         
                            <option value="robotics">Robotics</option>
                         
                            <option value="safety">Safety</option>
                         
                            <option value="sensors">Sensors</option>
                         
                            <option value="separations">Separations</option>
                         
                            <option value="sinusitis">Sinusitis</option>
                         
                            <option value="socsci">Social Sciences</option>
                         
                            <option value="societies">Societies</option>
                         
                            <option value="sports">Sports</option>
                         
                            <option value="sustainability">Sustainability</option>
                         
                            <option value="symmetry">Symmetry</option>
                         
                            <option value="systems">Systems</option>
                         
                            <option value="technologies">Technologies</option>
                         
                            <option value="toxics">Toxics</option>
                         
                            <option value="toxins">Toxins</option>
                         
                            <option value="tropicalmed">TropicalMed</option>
                         
                            <option value="universe">Universe</option>
                         
                            <option value="urbansci">Urban Science</option>
                         
                            <option value="vaccines">Vaccines</option>
                         
                            <option value="vetsci">Veterinary Sciences</option>
                         
                            <option value="viruses">Viruses</option>
                         
                            <option value="vision">Vision</option>
                         
                            <option value="water">Water</option>
                                        </select></td>
				<td style="text-align: center;"><div class="lb"><a href="/search" style="color: inherit; border-bottom: 1px dotted;">Advanced</a></div></td>
				            </tr>
            <tr>
                <td><div class="lb">Author</div></td>
                <td class="field"><input type="text" id="authors" tabindex="2" name="authors" value="" /></td>
                <td><div class="lb">Section</div></td>
                <td class="field"><select id="section" tabindex="5" name="section"><option value="">---</option></select></td>
									<td class="field" colspan="2"><input type="submit" id="search" value="Search" class="searchButton" tabindex="12" name="search" style="margin: 0 0 0 0; float:right;"></td>
							</tr>
            <tr>
                <td><div class="lb">Article Type</div></td>
                <td class="field"><select id="article_type" tabindex="3" name="article_type"><option value="">all</option>
                                                                            <option value="addendum">Addendum</option>
                                                    <option value="research-article">Article</option>
                                                    <option value="book-review">Book Review</option>
                                                    <option value="case-report">Case Report</option>
                                                    <option value="article-commentary">Comment</option>
                                                    <option value="commentary">Commentary</option>
                                                    <option value="rapid-communication">Communication</option>
                                                    <option value="concept-paper">Concept Paper</option>
                                                    <option value="conference-report">Conference Report</option>
                                                    <option value="correction">Correction</option>
                                                    <option value="creative">Creative</option>
                                                    <option value="data-descriptor">Data Descriptor</option>
                                                    <option value="discussion">Discussion</option>
                                                    <option value="editorial">Editorial</option>
                                                    <option value="erratum">Erratum</option>
                                                    <option value="essay">Essay</option>
                                                    <option value="expression-of-concern">Expression of Concern</option>
                                                    <option value="interesting-image">Interesting Images</option>
                                                    <option value="letter">Letter</option>
                                                    <option value="books-received">New Book Received</option>
                                                    <option value="obituary">Obituary</option>
                                                    <option value="opinion">Opinion</option>
                                                    <option value="project-report">Project Report</option>
                                                    <option value="reply">Reply</option>
                                                    <option value="retraction">Retraction</option>
                                                    <option value="review-article">Review</option>
                                                    <option value="note">Short Note</option>
                                                    <option value="technical-note">Technical Note</option>
                                        </select></td>
                <td><div class="lb">Special Issue</div></td>
                <td class="field"><select id="special_issue" tabindex="6" name="special_issue"><option value="">---</option></select></td>
                <td class="field" colspan="2"><input tabindex="9" type="reset" value="Clear" id="clear" class="submit" style="margin: 0 0 0 0; float:right;"></td>
                            </tr>
        </table></td> 
								
																<td style="width: 100%">

        

<div style="width: 100%; text-align: right;">
    <div style="margin-right: 0.5em; width: 130px; display: inline-block;">
        <div class="jif_parent" style="float:left"><div class="jif_floater">
                <a href="/about/anniversary20"><img width="75px" height="75px" src="http://img.mdpi.org/bundles/mdpimain/img/anniversary_logo_150px.png" style="vertical-align:middle;" alt="logo"></a>
            </div>
        </div>
        
        <div class="jif_parent">
                <div class="jif_floater">
                    <div class="jif_label">                        
                            <a href="/journal/molecules/stats" style="color: inherit; text-decoration: none;">                        
                                <span class="jif_text">IMPACT<br />FACTOR</span><br />
                                <span class="jif_number">2.465</span>
                            </a>
                                            </div>
                </div>
            </div>
            </div>
</div>
</td>

</tr></table>

</form></td>                            </tr>
                        </table>
                    </div>

                    <div id="main">
  <div id="leftcol">

	<div style="margin:0 0.9em 1em 0.6em; padding:0; background-color:#007F7F; border-bottom:0.5em solid #99CCCC;">
	<ul class="menu-journal">
		<li>
			<a style="color:#FFFFFF; text-decoration:underline;" href="/journal/molecules"><em>Molecules</em></a>
		</li>
		<li>
			<a style="color:#FFFFFF; text-decoration:underline;" href="/1420-3049/21/2">
				Volume 21, Issue 2
			</a>
		</li>
	</ul>
	</div>

                    <a href="/1420-3049/21/2">
                <img style="width: 164px;margin:0 0.9em 1em 0.6em;" src="http://img.mdpi.org/data/covers/molecules/cover-molecules-v21-i2.png" alt="Issue 2 (February) cover image"></img>
            </a>
                        
        
	        <div class="menu-caption"><span>Article Versions</span></div>
        <ul class="menu">

            <li><a href="http://www.mdpi.com/1420-3049/21/2/185">Abstract</a></li>

                    <li><a href="http://www.mdpi.com/1420-3049/21/2/185/htm">Full-Text HTML</a></li>
        
                    <li><a href="http://www.mdpi.com/1420-3049/21/2/185/pdf" onclick="javascript:urchinTracker('http://www.mdpi.com/1420-3049/21/2/185/pdf');">Full-Text PDF</a> <span class="size">[1271 KB]</span></li>
        
        
                    <li><a href="http://www.mdpi.com/1420-3049/21/2/185/xml" onclick="javascript:urchinTracker('http://www.mdpi.com/1420-3049/21/2/185/xml');">Full-Text XML</a></li>
        
                    <li><a href="http://www.mdpi.com/1420-3049/21/2/185/notes" onclick="javascript:urchinTracker('http://www.mdpi.com/1420-3049/21/2/185/notes');">Article Versions Notes</a></li>
        
        								   <li><a id=supplement_link href="http://www.mdpi.com/1420-3049/21/2/185#supplementary">Supplementary material</a></li>
		      	           </ul>
	
  <div class="menu-caption"><span>Related Info</span></div>
	<ul class="menu">
        		<li><a id=stats_link href="http://www.mdpi.com/1420-3049/21/2/185#stats">Article Statistics</a></li>		<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez/26861270" target="_blank">PubMed/Medline</a></li>		<li><a href="http://scholar.google.com/scholar?q=Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors" target="_blank">Google Scholar</a></li>
		<li><a href="http://www.mdpi.com/1420-3049/21/2/185/reprints">Order Reprints</a></li>
	</ul>

  <div class="menu-caption"><span>More by Authors</span></div>
	<ul class="menu">
		<li><a class="expand">[+] on DOAJ</a></li>
          <div id="AuthorDOAJExpand" style="display:none;">
            <ul class="submenu">
                           <li>
            <a href="http://doaj.org/search?source=%7B&quot;query&quot;:%7B&quot;query_string&quot;:%7B&quot;query&quot;:&quot;Milan+Remko&quot;,&quot;default_operator&quot;:&quot;AND&quot;%7D%7D%7D" target="_blank">Remko, M</a>
        </li>
            <li>
            <a href="http://doaj.org/search?source=%7B&quot;query&quot;:%7B&quot;query_string&quot;:%7B&quot;query&quot;:&quot;Anna+Remkov%C3%A1&quot;,&quot;default_operator&quot;:&quot;AND&quot;%7D%7D%7D" target="_blank">Remková, A</a>
        </li>
            <li>
            <a href="http://doaj.org/search?source=%7B&quot;query&quot;:%7B&quot;query_string&quot;:%7B&quot;query&quot;:&quot;Ria+Broer&quot;,&quot;default_operator&quot;:&quot;AND&quot;%7D%7D%7D" target="_blank">Broer, R</a>
        </li>
    
			</ul>
          </div>
		<li><a class="expand">[+] on Google Scholar</a></li>
		<div id="AuthorGoogleExpand" style="display:none;">
            <ul class="submenu">
                           <li>
            <a href="http://scholar.google.com/scholar?q=Milan+Remko" target="_blank">Remko, M</a>
        </li>
            <li>
            <a href="http://scholar.google.com/scholar?q=Anna+Remkov%C3%A1" target="_blank">Remková, A</a>
        </li>
            <li>
            <a href="http://scholar.google.com/scholar?q=Ria+Broer" target="_blank">Broer, R</a>
        </li>
    
			</ul>
          </div>

	<li><a class="expand">[+] on PubMed</a></li>
          <div id="AuthorPubMedExpand" style="display:none;">
            <ul class="submenu">
                           <li>
            <a href="http://www.pubmed.com/?cmd=Search&amp;term=Milan+Remko" target="_blank">Remko, M</a>
        </li>
            <li>
            <a href="http://www.pubmed.com/?cmd=Search&amp;term=Anna+Remkov%C3%A1" target="_blank">Remková, A</a>
        </li>
            <li>
            <a href="http://www.pubmed.com/?cmd=Search&amp;term=Ria+Broer" target="_blank">Broer, R</a>
        </li>
    
			</ul>
          </div>
	</ul>
  <div class="menu-caption"><span>Share This Article</span></div>
	<ul class="menu">
		<li><a href="http://twitter.com/home?status=%23mdpimolecules+Theoretical+Study+of+Molecular+Structure+and+Physicochemical+Properties+of+Novel+http%3A%2F%2Fwww.mdpi.com%2F1420-3049%2F21%2F2%2F185++%40Molecules_MDPI" onclick="windowOpen(this.href,600,800); return false"><img border="0" src="http://img.mdpi.org/img/icons/twitter_new.png?fd8dab924a348c64" width="16" height="16" class="textmiddle">&nbsp;Twitter</a></li>
		<li><a href="http://www.facebook.com/sharer.php?u=http://www.mdpi.com/1420-3049/21/2/185" target="_blank"><img border="0" src="http://img.mdpi.org/img/icons/facebook_new.png?2800a8d3985cf91d" width="16" height="16" class="textmiddle">&nbsp;Facebook</a></li>
		<li><a href="http://www.mendeley.com/import/?url=http://www.mdpi.com/1420-3049/21/2/185" target="_blank"><img border="0" src="http://img.mdpi.org/img/icons/mendeley_new.png?e4486db70babb78e" width="16" height="16" class="textmiddle">&nbsp;Mendeley</a></li>
		<li><a href="http://www.citeulike.org/posturl?url=http://www.mdpi.com/1420-3049/21/2/185" target="_blank"><img border="0" src="http://img.mdpi.org/img/icons/citeulike_new.jpg?46b2647c72fd5d8b" width="16" height="16" class="textmiddle">&nbsp;CiteULike</a></li>
	</ul>
		
            <div class="menu-caption" id="html-quick-links-title"> <span>Quick Links</span> </div>
	</div>
                        <div class="rightcol"></div>                        <link href="/assets/css/font-awesome.min.css" rel="stylesheet"><div id="maincol" style="position: relative;">
      
<ul class="menu html-nav" data-prev-node="#html-quick-links-title">
</ul>
<article>
  <div class='html-front'>
  <span class="html-oa-logo">
    <a href="http://www.mdpi.com/about/openaccess">
      Open Access
      <span class="html-oa-logo-extended" style="margin: 2px 0 0 -3px">This article is
        <ul>
          <li>freely available</li>
          <li>re-usable</li>
        </ul>
      </span>
    </a>
  </span>
  <div class="html-art-header">
    <p>
      <i>Molecules</i>
      <b>2016</b>,
      <i>21</i>(2),
      185;
      doi:<a href="http://dx.doi.org/10.3390/molecules21020185" target="_blank">10.3390/molecules21020185</a>
    </p>
  </div>

  <div class="html-art-type">
    Article
  </div>

  <div id="html-article-title">Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors</div>

  <div class="html-author-group">
    Milan Remko <sup><span data-rid='af1-molecules-21-00185'>1</span></sup><sup>,</sup><span data-rid='c1-molecules-21-00185'>*</span>,
    
    Anna Remková <sup><span data-rid='af2-molecules-21-00185'>2</span></sup>
    and
    Ria Broer <sup><span data-rid='af3-molecules-21-00185'>3</span></sup>
    
  </div>

  <div class="html-aff-group">
    <div class="html-aff" id=af1-molecules-21-00185 >
      <div class="html-label" >
        <sup data-label='1'>1</sup>
      </div>
      <div class="html-content" >Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, SK-832 32 Bratislava, Slovakia</div>
    </div>
    <div class="html-aff" id=af2-molecules-21-00185 >
      <div class="html-label" >
        <sup data-label='2'>2</sup>
      </div>
      <div class="html-content" >Department of Internal Medicine, Faculty of Medicine, Slovak Medical University, Limbová 12, SK-833 03 Bratislava, Slovakia</div>
    </div>
    <div class="html-aff" id=af3-molecules-21-00185 >
      <div class="html-label" >
        <sup data-label='3'>3</sup>
      </div>
      <div class="html-content" >Department of Theoretical Chemistry, Zernike Institute for Advanced Materials, University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands</div>
    </div>
  </div>

  <div class="html-notes">
    <div class="html-note" id=c1-molecules-21-00185>
      <div class="html-label">
        *
      </div>
      <div class="html-content"> Correspondence: Tel.: +421-2-5011-7291</div>
    </div>
  </div>


  <div class="html-external_editor">
    Academic Editor:
      James W. Gauld
      
  </div>

  <div class="html-history">
    Received: 11 January 2016 / Accepted: 27 January 2016 / Published: 4 February 2016
  </div>

  <section class="html-abstract" id="html-abstract">

      <h2 id="html-abstract-title">Abstract</h2><b>:</b>
      The geometries and energies of factor Xa inhibitors edoxaban, eribaxaban, fidexaban, darexaban, letaxaban, and the dual factor Xa and thrombin inhibitors tanogitran and SAR107375 in both the gas-phase and aqueous solution were studied using the Becke3LYP/6-31++G(d,p) or Grimme’s B97D/6-31++G(d,p) method. The fully optimized conformers of these anticoagulants show a characteristic <span class='html-small-caps'>l</span>-shape structure, and the water had a remarkable effect on the equilibrium geometry. According to the calculated p<span class='html-italic'>K</span>a values eribaxaban and letaxaban are in neutral undissociated form at pH 7.4, while fidexaban and tanogitran exist as zwitterionic structures. The lipophilicity of the inhibitors studied lies within a large range of log <span class='html-italic'>P</span> between 1 and 4. The dual inhibitor SAR107375 represents an improvement in structural, physicochemical and pharmacokinetic characteristics over tanogitran. At blood pH, SAR107375 predominantly exists in neutral form. In contrast with tanogitran, it is better absorbed and more lipophilic and active after oral application.

  </section>

  <div id="html-keywords">
    <div class='html-gwd-group'><div id='html-keywords-title'>Keywords:</div>
    density functional theory (DFT); anticoagulants; conformation; solvent effect; acidity; lipophilicity; absorption</div>

  </div>


</div>
  <div class="html-body">
    <section id='sec1-molecules-21-00185' type='intro'><h2 data-nested='1'>  1. Introduction</h2><div class='html-p'>During the last 65 years or so compounds from the vitamin K antagonists group (warfarin and its derivatives) have been the only available oral anticoagulants [<a href="#B1-molecules-21-00185" class="html-bibr">1</a>], but their use is complicated owing to wide inter-individual variability in dose requirements and their narrow therapeutic index [<a href="#B2-molecules-21-00185" class="html-bibr">2</a>,<a href="#B3-molecules-21-00185" class="html-bibr">3</a>]. Extensive pharmaceutical research in this field for the last 20–30 years has resulted in several new orally active anticoagulants with significant advantages compared to current drugs such as warfarin and low molecular weight heparin for the treatment and prevention of thrombotic diseases. The new anticoagulants studied for venous thromboembolism treatment inhibit factor Xa (FXa) or thrombin (FIIa). Numerous direct, selective fXa and/or thrombin inhibitors are at various stages of development [<a href="#B4-molecules-21-00185" class="html-bibr">4</a>,<a href="#B5-molecules-21-00185" class="html-bibr">5</a>,<a href="#B6-molecules-21-00185" class="html-bibr">6</a>]. Synthetic inhibitors such as betrixaban, razaxaban, eribaxaban, fidexaban, darexaban (YM150), letaxaban (TAK-442) are members of a new class of orally available fXa inhibitors. In addition to the abovementioned direct fXa inhibitors, dual thrombin/fXa inhibitors such as tanogitran, RWJ-445167, and SAR107375 have also been developed [<a href="#B7-molecules-21-00185" class="html-bibr">7</a>,<a href="#B8-molecules-21-00185" class="html-bibr">8</a>,<a href="#B9-molecules-21-00185" class="html-bibr">9</a>]. Despite a number of experimental structural information about binding models of novel anticoagulants targeting thrombin, fXa or both, experimental studies concerned with the systematic comparative studies of their physicochemical and pharmacokinetic parameters are scarce, and most of novel drug were discovered serendipitously [<a href="#B10-molecules-21-00185" class="html-bibr">10</a>]. In our previous work, direct fXa inhibitors (apixaban, rivaroxaban, otamixaban, betrixaban, razaxaban, and DX-9065a) and direct inhibitors of thrombin (ximelagatran and dabigatran etexilate) were studied theoretically [<a href="#B11-molecules-21-00185" class="html-bibr">11</a>,<a href="#B12-molecules-21-00185" class="html-bibr">12</a>].</div><div class='html-p'>In the work presented here we used density functional calculations for the detailed investigation of the molecular structure of direct fXa inhibitors edoxaban, eribaxaban, fidexaban, darexaban (YM150), letaxaban (TAK-442) and the dual factor Xa and thrombin inhibitors tanogitran and SAR107375. The effect of the solvent on the molecular structure of these drugs was evaluated using the polarizable continuum method. Our interest was also focused on the evaluation of basic physicochemical and pharmacokinetic properties (such as p<span class='html-italic'>K</span>a, lipophilicity, solubility, absorption, and polar surface area) of these species. Attention has also been given to comparison of theoretical results with published experimental properties of these drugs in the light of present theories of their action. These and previously studied anticoagulant drugs [<a href="#B11-molecules-21-00185" class="html-bibr">11</a>,<a href="#B12-molecules-21-00185" class="html-bibr">12</a>] have entered early and advanced stages of clinical development. Thus, the investigation of their molecular structures and physicochemical properties may contribute to understand the relationships between structure and activity and biological properties of novel anticoagulants.</div></section><section id='sec2-molecules-21-00185' type='results'><h2 data-nested='1'>  2. Results and Discussion</h2><section id='sec2dot1-molecules-21-00185' type=''><h4 class=html-italic data-nested='2'>  2.1. DFT Calculations of Molecular Structures</h4><div class='html-p'>The accurate determination of the geometry of chemical drugs is nowadays accessible through the application of sophisticated quantum chemistry methods [<a href="#B13-molecules-21-00185" class="html-bibr">13</a>]. Theoretical chemistry methods are now used in medicinal chemistry and drug design to accurately determine structure and properties of molecules for use in a wide variety of CADD investigations [<a href="#B14-molecules-21-00185" class="html-bibr">14</a>,<a href="#B15-molecules-21-00185" class="html-bibr">15</a>]. The starting conformations to use in the DFT calculations for these drugs were constructed using the Gauss View program. The spatial orientation of important functional groups of these molecules was defined by selected dihedral angles (α, β, γ, δ, ε, ζ, η, ν, θ, μ, ξ and ρ, <a href="#molecules-21-00185-f001" class="html-fig">Figure 1</a>, <a href="#molecules-21-00185-t001" class="html-table">Table 1</a>). The important structural parameters (dihedral angles) describing the relative molecular orientation of the studied drugs are presented in the <a href="#molecules-21-00185-t001" class="html-table">Table 1</a>. The Cartesian coordinates of all inhibitors studied, optimized at the B3LYP level of the density functional theory, are given in <a href="#app1-molecules-21-00185" class="html-app">Table S1</a>. Subsequent frequency computations of the harmonic vibrational frequencies of the optimized molecules revealed that all the structures obtained were minima (no imaginary frequencies). The equilibrium geometries of the studied drugs computed at the B3LYP and B97D levels of theory are presented in <a href="#app1-molecules-21-00185" class="html-app">Figure S1</a>. With respect to the nature of drugs studied, their conformational behavior was, in addition to the B3LYP method, also computed using the B97D functional, which includes dispersion. The B97D functional uses the empirical dispersion energy correction specifically designed for an accurate evaluation of van der Waals interactions [<a href="#B16-molecules-21-00185" class="html-bibr">16</a>]. <a href="#molecules-21-00185-t002" class="html-table">Table 2</a> shows the solvation energies obtained from calculations performed in a vacuum and calculations based on the solvation method. The energy difference between the gas phase and solvated phase was significant for both DFT functionals, B3LYP and B97D, applied in combination with the CPCM solvation model. The largest difference (55.5 kJ/mol) in solvation energies computed with these functionals was found for fidexaban. The different minimum energy conformations computed at the B3LYP and B97D levels of theory for this drug are apparently responsible for this difference (<a href="#molecules-21-00185-t001" class="html-table">Table 1</a> and <a href="#app1-molecules-21-00185" class="html-app">Figure S1</a>).</div><div class="html-fig-wrap" id="molecules-21-00185-f001">
  <div class='html-fig_img'>
    <div class="html-figpopup html-figpopup-link" href="#fig_body_display_molecules-21-00185-f001">
      <img alt="Molecules 21 00185 g001 1024" data-large="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g001-1024.png" data-original="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g001.png" src="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g001-1024.png" />
      <a class="html-expand html-figpopup" href="#fig_body_display_molecules-21-00185-f001"></a>
    </div>

  </div>
  <div class="html-fig_description">
    <b>Figure 1.</b>
      Structure and atom labeling in the anticoagulant drugs studied.
<!--     <p><a class="html-figpopup" href="#fig_body_display_molecules-21-00185-f001">
      Click here to enlarge figure
    </a></p> -->

  </div>
</div>
<div class="html-fig_show  mfp-hide" id ="fig_body_display_molecules-21-00185-f001" >
  <div class="html-caption" > <b>Figure 1.</b>
      Structure and atom labeling in the anticoagulant drugs studied.</div>
  <div class="html-img"><img alt="Molecules 21 00185 g001 1024" data-large="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g001-1024.png" data-original="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g001.png" src="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g001-1024.png" /></div>
</div><div class="html-table-wrap" id="molecules-21-00185-t001">
  <div class="html-table_wrap_td" >
    <div class="html-tablepopup html-tablepopup-link" href='#table_body_display_molecules-21-00185-t001'>
        <img alt="Table" src="http://img.mdpi.org/img/table.png" />
       <a class="html-expand html-tablepopup" href="#table_body_display_molecules-21-00185-t001"></a>
    </div>

  </div>
  <div class="html-table_wrap_discription">
    <b>Table 1.</b>
    Optimized dihedral angles (degrees) of the drugs studied.
  </div>
</div>
<div class="html-table_show  mfp-hide " id ="table_body_display_molecules-21-00185-t001" >
  
  <table >
    <caption ><b>Table 1.</b>
    Optimized dihedral angles (degrees) of the drugs studied.</caption>
    <thead  ><tr  ><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >Dihedral Angle <sup>a</sup></th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >X-ray <sup>b</sup></th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >B3LYP/6-31++g(p,d)</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >B97D/6-31++g(p,d)</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >B3LYP–CPCM</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >B97D–CPCM</th></tr></thead><tbody  ><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' ><b>(<span class='html-italic'>S</span>,<span class='html-italic'>R</span>,<span class='html-italic'>S</span>)-Edoxaban</b></td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td></tr><tr  ><td align='center' valign='middle' >α[S(1)-C(2)-C(3)-O(4)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−2.59</td><td align='center' valign='middle' >−2.77</td><td align='center' valign='middle' >−0.44</td><td align='center' valign='middle' >−0.38</td></tr><tr  ><td align='center' valign='middle' >β[S(1)-C(2)-C(3)-N(5)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >176.73</td><td align='center' valign='middle' >176.50</td><td align='center' valign='middle' >179.30</td><td align='center' valign='middle' >179.13</td></tr><tr  ><td align='center' valign='middle' >γ[C(2)-C(3)-N(5)-C(6)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >173.81</td><td align='center' valign='middle' >173.90</td><td align='center' valign='middle' >175.62</td><td align='center' valign='middle' >175.40</td></tr><tr  ><td align='center' valign='middle' >δ[C(3)-N(5)-C(6)-C(7)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >134.17</td><td align='center' valign='middle' >132.08</td><td align='center' valign='middle' >122.43</td><td align='center' valign='middle' >132.05</td></tr><tr  ><td align='center' valign='middle' >ε[C(6)-C(7)-N(8)-C(9)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−147.47</td><td align='center' valign='middle' >−154.20</td><td align='center' valign='middle' >−120.05</td><td align='center' valign='middle' >−144.15</td></tr><tr  ><td align='center' valign='middle' >ζ[C(7)-N(8)-C(9)-O(10)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >1.30</td><td align='center' valign='middle' >2.45</td><td align='center' valign='middle' >−0.50</td><td align='center' valign='middle' >3.10</td></tr><tr  ><td align='center' valign='middle' >η[C(7)-N(8)-C(9)-C(11)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−178.53</td><td align='center' valign='middle' >−177.58</td><td align='center' valign='middle' >179.45</td><td align='center' valign='middle' >−177.16</td></tr><tr  ><td align='center' valign='middle' >θ[N(8)-C(9)-C(11)]-O(12)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >1.90</td><td align='center' valign='middle' >2.83</td><td align='center' valign='middle' >−0.10</td><td align='center' valign='middle' >1.20</td></tr><tr  ><td align='center' valign='middle' >μ[N(8)-C(9)-C(11)]-N(13)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−178.53</td><td align='center' valign='middle' >−177.57</td><td align='center' valign='middle' >179.92</td><td align='center' valign='middle' >−179.06</td></tr><tr  ><td align='center' valign='middle' >ν[C(9)-C(11)]-N(13)-C(14)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−179.38</td><td align='center' valign='middle' >−179.90</td><td align='center' valign='middle' >179.69</td><td align='center' valign='middle' >−179.71</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' >ξ[C(11)]-N(13)-C(14)-N(15)]</td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' >179.16</td><td align='center' valign='middle' style='border-bottom:solid thin' >179.45</td><td align='center' valign='middle' style='border-bottom:solid thin' >−179.78</td><td align='center' valign='middle' style='border-bottom:solid thin' >−179.34</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' ><b>(<span class='html-italic'>R</span>,<span class='html-italic'>R</span>)-Eribaxaban</b></td><td align='center' valign='middle' style='border-bottom:solid thin' >2PHB</td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td></tr><tr  ><td align='center' valign='middle' >α[C(1)-N(2)-C(3)-C(4)]</td><td align='center' valign='middle' >−82.79</td><td align='center' valign='middle' >−58.39</td><td align='center' valign='middle' >−56.15</td><td align='center' valign='middle' >−96.18</td><td align='center' valign='middle' >−66.62</td></tr><tr  ><td align='center' valign='middle' >β[C(5)-C(6)-N(7)-C(8)]</td><td align='center' valign='middle' >65.14</td><td align='center' valign='middle' >4.19</td><td align='center' valign='middle' >−12.63</td><td align='center' valign='middle' >5.85</td><td align='center' valign='middle' >−17.44</td></tr><tr  ><td align='center' valign='middle' >γ[C(6)-N(7)-C(8)-O(9)]</td><td align='center' valign='middle' >−0.09</td><td align='center' valign='middle' >−4.81</td><td align='center' valign='middle' >1.63</td><td align='center' valign='middle' >−2.73</td><td align='center' valign='middle' >0.77</td></tr><tr  ><td align='center' valign='middle' >δ[C(6)-N(7)-C(8)-C(10)]</td><td align='center' valign='middle' >179.50</td><td align='center' valign='middle' >176.37</td><td align='center' valign='middle' >−175.78</td><td align='center' valign='middle' >178.01</td><td align='center' valign='middle' >−176.90</td></tr><tr  ><td align='center' valign='middle' >ε[N(7)-C(8)-C(10)-N(11)]</td><td align='center' valign='middle' >1.67</td><td align='center' valign='middle' >7.42</td><td align='center' valign='middle' >65.65</td><td align='center' valign='middle' >4.84</td><td align='center' valign='middle' >63.15</td></tr><tr  ><td align='center' valign='middle' >ζ[C(10)-N(11)-C(12)-O(13)]</td><td align='center' valign='middle' >−0.39</td><td align='center' valign='middle' >155.21</td><td align='center' valign='middle' >164.51</td><td align='center' valign='middle' >161.65</td><td align='center' valign='middle' >169.76</td></tr><tr  ><td align='center' valign='middle' >η[C(10)-N(11)-C(12)-N(14)]</td><td align='center' valign='middle' >179.24</td><td align='center' valign='middle' >−26.05</td><td align='center' valign='middle' >−16.00</td><td align='center' valign='middle' >−19.78</td><td align='center' valign='middle' >−10.78</td></tr><tr  ><td align='center' valign='middle' >θ[N(11)-C(12)-N(14)]-C(15)]</td><td align='center' valign='middle' >168.30</td><td align='center' valign='middle' >179.48</td><td align='center' valign='middle' >−178.64</td><td align='center' valign='middle' >−179.29</td><td align='center' valign='middle' >−177.55</td></tr><tr  ><td align='center' valign='middle' >μ[C(12)-N(14)]-C(15)-C(16)]</td><td align='center' valign='middle' >−155.47</td><td align='center' valign='middle' >176.92</td><td align='center' valign='middle' >174.63</td><td align='center' valign='middle' >175.98</td><td align='center' valign='middle' >170.63</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' >H-bond MeO···H-N, Å</td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' >2.9338</td><td align='center' valign='middle' style='border-bottom:solid thin' >1.8796</td><td align='center' valign='middle' style='border-bottom:solid thin' >3.0505</td><td align='center' valign='middle' style='border-bottom:solid thin' >1.8373</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' ><b>Fidexaban</b></td><td align='center' valign='middle' style='border-bottom:solid thin' >1FJS</td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td></tr><tr  ><td align='center' valign='middle' >α[N(1)-C(2)-C(3)-C(4)]</td><td align='center' valign='middle' >−87.79</td><td align='center' valign='middle' >−41.41</td><td align='center' valign='middle' >−39.50</td><td align='center' valign='middle' >−46.24</td><td align='center' valign='middle' >−43.11</td></tr><tr  ><td align='center' valign='middle' >β[C(4)-C(5)-O(6)-C(7)]</td><td align='center' valign='middle' >147.64</td><td align='center' valign='middle' >154.48</td><td align='center' valign='middle' >161.22</td><td align='center' valign='middle' >162.20</td><td align='center' valign='middle' >161.65</td></tr><tr  ><td align='center' valign='middle' >γ[C(5)-O(6)-C(7)-N(8)]</td><td align='center' valign='middle' >115.45</td><td align='center' valign='middle' >115.13</td><td align='center' valign='middle' >121.46</td><td align='center' valign='middle' >115.40</td><td align='center' valign='middle' >121.26</td></tr><tr  ><td align='center' valign='middle' >δ[N(8)-C(9)-O(10)-C(11)]</td><td align='center' valign='middle' >32.16</td><td align='center' valign='middle' >−19.64</td><td align='center' valign='middle' >−106.05</td><td align='center' valign='middle' >−12.40</td><td align='center' valign='middle' >−20.05</td></tr><tr  ><td align='center' valign='middle' >ε[C(9)-O(10)-C(11)-C(12)]</td><td align='center' valign='middle' >−120.44</td><td align='center' valign='middle' >−57.75</td><td align='center' valign='middle' >9.65</td><td align='center' valign='middle' >−69.17</td><td align='center' valign='middle' >−69.45</td></tr><tr  ><td align='center' valign='middle' >ζ[C(12)-C(13)-C(14)-N(15)]</td><td align='center' valign='middle' >−4.70</td><td align='center' valign='middle' >−21.84</td><td align='center' valign='middle' >−28.47</td><td align='center' valign='middle' >−25.67</td><td align='center' valign='middle' >−25.18</td></tr><tr  ><td align='center' valign='middle' >η[C(16)-C(17)-N(18)-C(19)]</td><td align='center' valign='middle' >−83.09</td><td align='center' valign='middle' >−132.13</td><td align='center' valign='middle' >57.97</td><td align='center' valign='middle' >−133.91</td><td align='center' valign='middle' >54.12</td></tr><tr  ><td align='center' valign='middle' >θ[C(17)-N(18)-C(19)-C(20)]</td><td align='center' valign='middle' >54.20</td><td align='center' valign='middle' >85.14</td><td align='center' valign='middle' >59.75</td><td align='center' valign='middle' >85.54</td><td align='center' valign='middle' >80.03</td></tr><tr  ><td align='center' valign='middle' >μ[N(18)-C(19)-C(20)-O(21)]</td><td align='center' valign='middle' >92.47</td><td align='center' valign='middle' >157.26</td><td align='center' valign='middle' >−170.74</td><td align='center' valign='middle' >164.70</td><td align='center' valign='middle' >162.60</td></tr><tr  ><td align='center' valign='middle' >H-bond OH···O, Å</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >2.1810</td><td align='center' valign='middle' >2.1949</td><td align='center' valign='middle' >2.2247</td><td align='center' valign='middle' >2.2777</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' >H-bond C(=O)OH···N, Å</td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' >No interaction</td><td align='center' valign='middle' style='border-bottom:solid thin' >1.5433</td><td align='center' valign='middle' style='border-bottom:solid thin' >No interaction</td><td align='center' valign='middle' style='border-bottom:solid thin' >No interaction</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' ><b>Darexaban</b></td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td></tr><tr  ><td align='center' valign='middle' >α[C(1)-C(2)-N(3)-C(4)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >42.45</td><td align='center' valign='middle' >−27.23</td><td align='center' valign='middle' >44.41</td><td align='center' valign='middle' >−33.72</td></tr><tr  ><td align='center' valign='middle' >β[C(2)-N(3)-C(4)-O(5)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−3.16</td><td align='center' valign='middle' >15.93</td><td align='center' valign='middle' >−5.24</td><td align='center' valign='middle' >15.21</td></tr><tr  ><td align='center' valign='middle' >γ[C(2)-N(3)-C(4)-C(6)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >176.75</td><td align='center' valign='middle' >−165.63</td><td align='center' valign='middle' >174.85</td><td align='center' valign='middle' >−165.63</td></tr><tr  ><td align='center' valign='middle' >δ[ N(3)-C(4)-C(6)-C(7)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >0.40</td><td align='center' valign='middle' >38.24</td><td align='center' valign='middle' >−1.49</td><td align='center' valign='middle' >36.32</td></tr><tr  ><td align='center' valign='middle' >ε[C(8)-C(9)-N(10)-C(11)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−15.09</td><td align='center' valign='middle' >−19.65</td><td align='center' valign='middle' >−11.84</td><td align='center' valign='middle' >−15.62</td></tr><tr  ><td align='center' valign='middle' >ζ[C(2)-C(12)-N(13)-C(14)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−55.13</td><td align='center' valign='middle' >−69.03</td><td align='center' valign='middle' >−55.92</td><td align='center' valign='middle' >−67.97</td></tr><tr  ><td align='center' valign='middle' >η[C(12)-N(13)-C(14)-O(15)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >6.59</td><td align='center' valign='middle' >−6.97</td><td align='center' valign='middle' >5.36</td><td align='center' valign='middle' >−8.64</td></tr><tr  ><td align='center' valign='middle' >θ[C(12)-N(13)-C(14)-C(16)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−173.43</td><td align='center' valign='middle' >167.34</td><td align='center' valign='middle' >−175.12</td><td align='center' valign='middle' >166.62</td></tr><tr  ><td align='center' valign='middle' >μ[N(13)-C(14)-C(16)-C(17)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >156.76</td><td align='center' valign='middle' >167.28</td><td align='center' valign='middle' >157.74</td><td align='center' valign='middle' >164.95</td></tr><tr  ><td align='center' valign='middle' >H-bond OH···O, Å</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >1.6197</td><td align='center' valign='middle' >1.5871</td><td align='center' valign='middle' >1.6089</td><td align='center' valign='middle' >1.5627</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' >H-bond NH···O, Å</td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' >1.8333</td><td align='center' valign='middle' style='border-bottom:solid thin' >2.9243</td><td align='center' valign='middle' style='border-bottom:solid thin' >1.8388</td><td align='center' valign='middle' style='border-bottom:solid thin' >3.0555</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' ><b>(<span class='html-italic'>S</span>)-Letaxaban</b></td><td align='center' valign='middle' style='border-bottom:solid thin' >3KL6</td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td></tr><tr  ><td align='center' valign='middle' >α[C(1)-C(2)-S(3)-C(4)]</td><td align='center' valign='middle' >106.69</td><td align='center' valign='middle' >95.99</td><td align='center' valign='middle' >99.47</td><td align='center' valign='middle' >96.34</td><td align='center' valign='middle' >93.17</td></tr><tr  ><td align='center' valign='middle' >β[C(2)-S(3)-C(4)-C(5)]</td><td align='center' valign='middle' >−76.01</td><td align='center' valign='middle' >−84.63</td><td align='center' valign='middle' >−76.11</td><td align='center' valign='middle' >−77.49</td><td align='center' valign='middle' >−55.63</td></tr><tr  ><td align='center' valign='middle' >γ[S(3)-C(4)-C(5)-O(6)]</td><td align='center' valign='middle' >71.15</td><td align='center' valign='middle' >73.11</td><td align='center' valign='middle' >74.21</td><td align='center' valign='middle' >72.76</td><td align='center' valign='middle' >85.44</td></tr><tr  ><td align='center' valign='middle' >δ[S(3)-C(4)-C(5)-C(7)]</td><td align='center' valign='middle' >−170.80</td><td align='center' valign='middle' >−167.10</td><td align='center' valign='middle' >−166.10</td><td align='center' valign='middle' >−168.99</td><td align='center' valign='middle' >−156.90</td></tr><tr  ><td align='center' valign='middle' >ε[C(4)-C(5)-C(7)-N(8)]</td><td align='center' valign='middle' >177.43</td><td align='center' valign='middle' >165.01</td><td align='center' valign='middle' >163.51</td><td align='center' valign='middle' >144.15</td><td align='center' valign='middle' >168.58</td></tr><tr  ><td align='center' valign='middle' >ζ [C(5)-C(7)-N(8)]-C(9)]</td><td align='center' valign='middle' >178.57</td><td align='center' valign='middle' >176.96</td><td align='center' valign='middle' >171.50</td><td align='center' valign='middle' >179.43</td><td align='center' valign='middle' >171.71</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' >η[C(10)-C(11)-N(12)-C(13)]</td><td align='center' valign='middle' style='border-bottom:solid thin' >103.92</td><td align='center' valign='middle' style='border-bottom:solid thin' >124.08</td><td align='center' valign='middle' style='border-bottom:solid thin' >130.11</td><td align='center' valign='middle' style='border-bottom:solid thin' >113.62</td><td align='center' valign='middle' style='border-bottom:solid thin' >110.42</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' ><b>(<span class='html-italic'>R</span>)-Tanogitran</b></td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td></tr><tr  ><td align='center' valign='middle' >α[N(1)-C(2)-C(3)-C(4)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−20.46</td><td align='center' valign='middle' >−18.73</td><td align='center' valign='middle' >−24.41</td><td align='center' valign='middle' >−23.77</td></tr><tr  ><td align='center' valign='middle' >β[C(5)-C(6)-N(7)-C(8)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >165.54</td><td align='center' valign='middle' >−157.23</td><td align='center' valign='middle' >166.83</td><td align='center' valign='middle' >−158.63</td></tr><tr  ><td align='center' valign='middle' >γ[C(6)-N(7)-C(8)-C(9)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >79.48</td><td align='center' valign='middle' >49.24</td><td align='center' valign='middle' >80.05</td><td align='center' valign='middle' >49.22</td></tr><tr  ><td align='center' valign='middle' >δ[N(7)-C(8)-C(9)-N(10)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−125.14</td><td align='center' valign='middle' >−115.94</td><td align='center' valign='middle' >−123.21</td><td align='center' valign='middle' >−118.50</td></tr><tr  ><td align='center' valign='middle' >ε[C(11)-C(12)-C(13)-C(14)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >31.69</td><td align='center' valign='middle' >38.45</td><td align='center' valign='middle' >34.23</td><td align='center' valign='middle' >38.52</td></tr><tr  ><td align='center' valign='middle' >ζ[C(11)-C(12)-C(13)-N(17)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−87.36</td><td align='center' valign='middle' >−80.82</td><td align='center' valign='middle' >−83.75</td><td align='center' valign='middle' >−80.04</td></tr><tr  ><td align='center' valign='middle' >η[C(12)-C(13)-N(17)-C(18)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−177.45</td><td align='center' valign='middle' >−177.20</td><td align='center' valign='middle' >−174.71</td><td align='center' valign='middle' >−174.96</td></tr><tr  ><td align='center' valign='middle' >ν[C(13)-N(17)-C(18)-C(19)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−164.74</td><td align='center' valign='middle' >−163.43</td><td align='center' valign='middle' >−164.14</td><td align='center' valign='middle' >−164.20</td></tr><tr  ><td align='center' valign='middle' >θ[N(17)-C(18)-C(19)-O(20)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >16.24</td><td align='center' valign='middle' >17.08</td><td align='center' valign='middle' >15.28</td><td align='center' valign='middle' >16.42</td></tr><tr  ><td align='center' valign='middle' >μ[C(12)-C(13)-C(14)-N(15)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >70.94</td><td align='center' valign='middle' >64.97</td><td align='center' valign='middle' >72.13</td><td align='center' valign='middle' >66.74</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' >ξ[C(13)-C(14)-N(15)-C(16)]</td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' >−177.86</td><td align='center' valign='middle' style='border-bottom:solid thin' >−171.37</td><td align='center' valign='middle' style='border-bottom:solid thin' >−178.37</td><td align='center' valign='middle' style='border-bottom:solid thin' >−174.10</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' ><b>(<span class='html-italic'>S</span>)-SAR107375</b></td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' > </td></tr><tr  ><td align='center' valign='middle' >α[S(1)-C(2)-C(3)-O(4)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−4.12</td><td align='center' valign='middle' >−5.85</td><td align='center' valign='middle' >−2.08</td><td align='center' valign='middle' >−0.81</td></tr><tr  ><td align='center' valign='middle' >β[S(1)-C(2)-C(3)-N(5)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >176.91</td><td align='center' valign='middle' >175.47</td><td align='center' valign='middle' >178.21</td><td align='center' valign='middle' >−179.81</td></tr><tr  ><td align='center' valign='middle' >γ[C(2)-C(3)-N(5)-C(6)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−178.37</td><td align='center' valign='middle' >−169.31</td><td align='center' valign='middle' >179.46</td><td align='center' valign='middle' >−172.09</td></tr><tr  ><td align='center' valign='middle' >δ[C(3)-N(5)-C(6)-C(7)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >101.01</td><td align='center' valign='middle' >90.58</td><td align='center' valign='middle' >115.31</td><td align='center' valign='middle' >92.59</td></tr><tr  ><td align='center' valign='middle' >ε[N(5)-C(6)-C(7)-C(8)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−60.05</td><td align='center' valign='middle' >−57.45</td><td align='center' valign='middle' >−62.20</td><td align='center' valign='middle' >−59.89</td></tr><tr  ><td align='center' valign='middle' >ζ[C(6)-C(7)-C(8)-N(9)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−71.35</td><td align='center' valign='middle' >−78.07</td><td align='center' valign='middle' >−73.08</td><td align='center' valign='middle' >−82.25</td></tr><tr  ><td align='center' valign='middle' >η[C(7)-C(8)-N(9)-C(10)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >169.79</td><td align='center' valign='middle' >172.87</td><td align='center' valign='middle' >173.19</td><td align='center' valign='middle' >177.96</td></tr><tr  ><td align='center' valign='middle' >ν[N(5)-C(6)-C(7)-N(11)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >58.89</td><td align='center' valign='middle' >63.57</td><td align='center' valign='middle' >56.60</td><td align='center' valign='middle' >61.56</td></tr><tr  ><td align='center' valign='middle' >θ[C(6)-C(7)-N(11)-S(12)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >106.96</td><td align='center' valign='middle' >129.39</td><td align='center' valign='middle' >105.71</td><td align='center' valign='middle' >135.19</td></tr><tr  ><td align='center' valign='middle' >μ[C(7)-N(11)-S(12)-C(13)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >65.20</td><td align='center' valign='middle' >52.66</td><td align='center' valign='middle' >62.55</td><td align='center' valign='middle' >53.58</td></tr><tr  ><td align='center' valign='middle' >ξ[N(11)-S(12)-C(13)-C(14)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >62.25</td><td align='center' valign='middle' >61.92</td><td align='center' valign='middle' >63.94</td><td align='center' valign='middle' >66.16</td></tr><tr  ><td align='center' valign='middle' >ρ[C(14)-C(15)-N(16)-C(17)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >117.02</td><td align='center' valign='middle' >141.33</td><td align='center' valign='middle' >98.19</td><td align='center' valign='middle' >113.44</td></tr><tr  ><td align='center' valign='middle' >σ[N(9)-C(8)-C(7)-N(11)]</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >168.87</td><td align='center' valign='middle' >160.95</td><td align='center' valign='middle' >166.80</td><td align='center' valign='middle' >156.52</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' >d[O(4)…S(1)], Å</td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' >2.9491</td><td align='center' valign='middle' style='border-bottom:solid thin' >2.9876</td><td align='center' valign='middle' style='border-bottom:solid thin' >2.9378</td><td align='center' valign='middle' style='border-bottom:solid thin' >2.9795</td></tr></tbody>
  </table>
  <div class='html-table_foot html-p'><div class='html-p' style='text-indent:0em;'><span class='html-fn-content'><sup>a</sup> For definition of dihedral angles see <a href="#molecules-21-00185-f001" class="html-fig">Figure 1</a>; <sup>b</sup> Protein Data Bank. <a href='http://www.rscb.org/pdb/' target='_blank'>http://www.rscb.org/pdb/</a>.</span></div></div>
</div><div class="html-table-wrap" id="molecules-21-00185-t002">
  <div class="html-table_wrap_td" >
    <div class="html-tablepopup html-tablepopup-link" href='#table_body_display_molecules-21-00185-t002'>
        <img alt="Table" src="http://img.mdpi.org/img/table.png" />
       <a class="html-expand html-tablepopup" href="#table_body_display_molecules-21-00185-t002"></a>
    </div>

  </div>
  <div class="html-table_wrap_discription">
    <b>Table 2.</b>
    The solvent stability (water) of the drugs studied.
  </div>
</div>
<div class="html-table_show  mfp-hide " id ="table_body_display_molecules-21-00185-t002" >
  
  <table >
    <caption ><b>Table 2.</b>
    The solvent stability (water) of the drugs studied.</caption>
    <thead  ><tr  ><th rowspan='2' align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >Drug</th><th colspan='2' align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >ΔE<sup>CPCM</sup>, kJ/mol</th><th colspan='2' align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >Gas-phase Dipole Moment, Debye (D)</th></tr><tr  ><th align='center' valign='middle' style='border-bottom:solid thin' >B3LYP–CPCM</th><th align='center' valign='middle' style='border-bottom:solid thin' >B97D–CPCM</th><th align='center' valign='middle' style='border-bottom:solid thin' >B3LYP/6-31++g(p,d)</th><th align='center' valign='middle' style='border-bottom:solid thin' >B97D/6-31++g(p,d)</th></tr></thead><tbody  ><tr  ><td align='center' valign='middle' >Edoxaban</td><td align='center' valign='middle' >−77.48</td><td align='center' valign='middle' >−73.67</td><td align='center' valign='middle' >9.54</td><td align='center' valign='middle' >9.16</td></tr><tr  ><td align='center' valign='middle' >Eribaxaban</td><td align='center' valign='middle' >−75.99</td><td align='center' valign='middle' >−68.57</td><td align='center' valign='middle' >1.86</td><td align='center' valign='middle' >6.61</td></tr><tr  ><td align='center' valign='middle' >Fidexaban</td><td align='center' valign='middle' >−90.60</td><td align='center' valign='middle' >−37.07</td><td align='center' valign='middle' >3.33</td><td align='center' valign='middle' >5.93</td></tr><tr  ><td align='center' valign='middle' >Darexaban</td><td align='center' valign='middle' >−65.66</td><td align='center' valign='middle' >−72.67</td><td align='center' valign='middle' >9.89</td><td align='center' valign='middle' >11.87</td></tr><tr  ><td align='center' valign='middle' >Letaxaban</td><td align='center' valign='middle' >−95.09</td><td align='center' valign='middle' >−93.43</td><td align='center' valign='middle' >8.45</td><td align='center' valign='middle' >7.39</td></tr><tr  ><td align='center' valign='middle' >Tanogitran</td><td align='center' valign='middle' >−101.56</td><td align='center' valign='middle' >−100.15</td><td align='center' valign='middle' >5.75</td><td align='center' valign='middle' >5.31</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' >SAR107375</td><td align='center' valign='middle' style='border-bottom:solid thin' >−89.02</td><td align='center' valign='middle' style='border-bottom:solid thin' >−79.57</td><td align='center' valign='middle' style='border-bottom:solid thin' >6.74</td><td align='center' valign='middle' style='border-bottom:solid thin' >4.62</td></tr></tbody>
  </table>
  
</div><section id='sec2dot1dot1-molecules-21-00185' type=''><h4 class= data-nested='3'>  2.1.1. Edoxaban</h4><div class='html-p'>Edoxaban (<span class='html-italic'>N</span>-(5-chloropyridin-2-yl)-<span class='html-italic'>N</span>′-[(1<span class='html-italic'>S</span>,2<span class='html-italic'>R</span>,4<span class='html-italic'>S</span>)-4-[(dimethylamino)carbonyl]-2-[[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]ethanediamide) is the third fXa inhibitor which was approved by the FDA in 2015 [<a href="#B17-molecules-21-00185" class="html-bibr">17</a>]. Edoxaban is a flexible molecule, and its overall space arrangement is defined by 11 dihedral angles (<a href="#molecules-21-00185-f001" class="html-fig">Figure 1</a>). The overall shape of its equilibrium geometry is shown on <a href="#app1-molecules-21-00185" class="html-app">Figure S1</a>. The calculated molecular conformation of edoxaban is directed by the stereochemistry of the substituents on the central cyclohexane ring. Cyclohexane is present in the more stable chair-shaped conformation [<a href="#B18-molecules-21-00185" class="html-bibr">18</a>]. Biologically active edoxaban exists as a pure diastereomer. Substituents at the chiral C-1 and C-4 carbon atoms of cyclohexane adopt the (<span class='html-italic'>S</span>)<span class='html-italic'>-</span>configuration and the C-2 substituents of this drug are in the (<span class='html-italic'>R</span>)-conformation. In this diastereomer, the 3D structure of edoxaban, like other direct fXa inhibitors, is characterized by a unique <span class='html-small-caps'>l</span>-shaped arrangement of the molecule. The chloropyridinyl, amide and <span class='html-italic'>N</span>,<span class='html-italic'>N</span>-dimethylcarbamoyl moieties are positioned linearly at the C-1 and C-4 atoms of cyclohexane. The thiazole skeleton is oriented perpendicularly to the plane of the cyclohexane ring to ensure <span class='html-small-caps'>l</span>-shaped 3D structure of this drug (<a href="#app1-molecules-21-00185" class="html-app">Figure S1</a>). The 3D structure computed with B3LYP and B97D DFT functionals was almost the same with slight differences in the dihedral angles of about 2–4° (<a href="#molecules-21-00185-t001" class="html-table">Table 1</a>). Upon solvation, the greatest changes by about 10° were observed in the torsion angle ε[C(6)-C(7)-N(8)-C(9)] of the chloropyridinyl moiety. (<a href="#molecules-21-00185-f002" class="html-fig">Figure 2</a>).</div><div class="html-fig-wrap" id="molecules-21-00185-f002">
  <div class='html-fig_img'>
    <div class="html-figpopup html-figpopup-link" href="#fig_body_display_molecules-21-00185-f002">
      <img alt="Molecules 21 00185 g002 1024" data-large="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g002-1024.png" data-original="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g002.png" src="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g002-1024.png" />
      <a class="html-expand html-figpopup" href="#fig_body_display_molecules-21-00185-f002"></a>
    </div>

  </div>
  <div class="html-fig_description">
    <b>Figure 2.</b>
      Molecular superimposition of the Becke3LYP optimized molecular structure of edoxaban (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="#006600" mathvariant="bold">green</mtext>
            </mrow>
          </semantics>
        </math>) and hydrated edoxaban (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="red" mathvariant="bold">red</mtext>
            </mrow>
          </semantics>
        </math>). For simplicity the hydrogen atoms are omitted.
<!--     <p><a class="html-figpopup" href="#fig_body_display_molecules-21-00185-f002">
      Click here to enlarge figure
    </a></p> -->

  </div>
</div>
<div class="html-fig_show  mfp-hide" id ="fig_body_display_molecules-21-00185-f002" >
  <div class="html-caption" > <b>Figure 2.</b>
      Molecular superimposition of the Becke3LYP optimized molecular structure of edoxaban (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="#006600" mathvariant="bold">green</mtext>
            </mrow>
          </semantics>
        </math>) and hydrated edoxaban (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="red" mathvariant="bold">red</mtext>
            </mrow>
          </semantics>
        </math>). For simplicity the hydrogen atoms are omitted.</div>
  <div class="html-img"><img alt="Molecules 21 00185 g002 1024" data-large="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g002-1024.png" data-original="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g002.png" src="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g002-1024.png" /></div>
</div></section><section id='sec2dot1dot2-molecules-21-00185' type=''><h4 class= data-nested='3'>  2.1.2. Eribaxaban</h4><div class='html-p'>(<span class='html-italic'>R,R</span>)-Eribaxaban ((2R,4R)-N-(4-chlorophenyl)-N-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide] is a proline-based fXa inhibitor discovered by Kohrt <span class='html-italic'>et al.</span> [<a href="#B19-molecules-21-00185" class="html-bibr">19</a>]; it entered phase II clinical trials, although its development was later disrupted in favor of apixaban [<a href="#B20-molecules-21-00185" class="html-bibr">20</a>]. The pharmacologically active diastereomer of eribaxaban represents a conformation in which both substituents at the C-2 and C-4 asymmetric carbon atoms of the proline moiety are in in the form of (<span class='html-italic'>R</span>)-stereoisomers. The full B3LYP optimization of this diastereomer gave the typical <span class='html-small-caps'>l</span>-shaped 3D conformer. A rather different overall shape of this molecule resulted from the B97D calculations. The final energy minimum is fixed via two intramolecular hydrogen bonds formed by the amide moiety of the C-2 proline substituent and the neighboring methoxy and proline amide moieties (<a href="#app1-molecules-21-00185" class="html-app">Figure S1</a>). Thus, by intramolecular hydrogen bonds, the stabilized conformer is also retained in hydrated eribaxaban (<a href="#molecules-21-00185-t001" class="html-table">Table 1</a>). The conformation of eribaxaban bound to fXa (PDB file 2PHB) differs from the gas-phase conformation and/or hydrated molecule at two points. The phenylpyridone ring is in the cavity of receptor rotated out of the amide plane by about 65°; the B3LYP calculation predicted coplanarity of this fragment (dihedral angle β[C(5)-C(6)-N(7)-C(8)] = 4.2°). The almost planar arrangement observed for the scaffold containing the chlorophenyl moiety and the proline group in bound eribaxaban is, in the isolated molecule, more relaxed to the periplanar conformation (dihedral angle η[C(10)-N(11)-C(12)-N(14)] = −26°). The structures of the isolated molecule and eribaxaban when bound to fXa (pdb code 2BJ5) are quite different (<a href="#molecules-21-00185-f003" class="html-fig">Figure 3</a>). The large difference in molecular conformations of bound and unbound eribaxaban are also manifested by large energy difference, and the biologically active conformation has a substantially higher energy (640 kJ/mol, B3LYP method) in comparison with the energy of the fully optimized structure. The solvent does not appreciably change the 3D structure of unbound molecule.</div><div class="html-fig-wrap" id="molecules-21-00185-f003">
  <div class='html-fig_img'>
    <div class="html-figpopup html-figpopup-link" href="#fig_body_display_molecules-21-00185-f003">
      <img alt="Molecules 21 00185 g003 1024" data-large="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g003-1024.png" data-original="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g003.png" src="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g003-1024.png" />
      <a class="html-expand html-figpopup" href="#fig_body_display_molecules-21-00185-f003"></a>
    </div>

  </div>
  <div class="html-fig_description">
    <b>Figure 3.</b>
      Molecular superimposition of the Becke3LYP optimized molecular structure of (<span class='html-italic'>R,R</span>)-eribaxaban (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="#006600" mathvariant="bold">green</mtext>
            </mrow>
          </semantics>
        </math>), in solution optimized (<span class='html-italic'>R,R</span>)-eribaxaban (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="red" mathvariant="bold">red</mtext>
            </mrow>
          </semantics>
        </math>) and (<span class='html-italic'>R,R</span>)-eribaxaban from the co-crystal with coagulation factor Xa, PDB.2PHB (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="blue" mathvariant="bold">blue</mtext>
            </mrow>
          </semantics>
        </math>). For simplicity the hydrogen atoms are omitted.
<!--     <p><a class="html-figpopup" href="#fig_body_display_molecules-21-00185-f003">
      Click here to enlarge figure
    </a></p> -->

  </div>
</div>
<div class="html-fig_show  mfp-hide" id ="fig_body_display_molecules-21-00185-f003" >
  <div class="html-caption" > <b>Figure 3.</b>
      Molecular superimposition of the Becke3LYP optimized molecular structure of (<span class='html-italic'>R,R</span>)-eribaxaban (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="#006600" mathvariant="bold">green</mtext>
            </mrow>
          </semantics>
        </math>), in solution optimized (<span class='html-italic'>R,R</span>)-eribaxaban (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="red" mathvariant="bold">red</mtext>
            </mrow>
          </semantics>
        </math>) and (<span class='html-italic'>R,R</span>)-eribaxaban from the co-crystal with coagulation factor Xa, PDB.2PHB (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="blue" mathvariant="bold">blue</mtext>
            </mrow>
          </semantics>
        </math>). For simplicity the hydrogen atoms are omitted.</div>
  <div class="html-img"><img alt="Molecules 21 00185 g003 1024" data-large="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g003-1024.png" data-original="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g003.png" src="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g003-1024.png" /></div>
</div></section><section id='sec2dot1dot3-molecules-21-00185' type=''><h4 class= data-nested='3'>  2.1.3. Fidexaban</h4><div class='html-p'>Fidexaban (<span class='html-italic'>N</span>-{2-(5-carbamimidoyl-2-hydroxyphenoxy)-3,5-difluoro-6-[3-(1-methyl-4,5-dihydro-1<span class='html-italic'>H</span>-imidazol-2-yl)phenoxy]-4-pyridinyl}-<span class='html-italic'>N</span>-methylglycine) is a parenteral agent that was advanced to human clinical trials [<a href="#B21-molecules-21-00185" class="html-bibr">21</a>,<a href="#B22-molecules-21-00185" class="html-bibr">22</a>]. The enoxypyridine and phenyoxyimidazoline scaffolds are considered to be in the favored <span class='html-italic'>syn</span> conformation [<a href="#B21-molecules-21-00185" class="html-bibr">21</a>]. The sarcosine at C-4 of the central pyridine ring is maximally extended. The two DFT methods applied describe the molecular structure of fidexaban quite differently (<a href="#app1-molecules-21-00185" class="html-app">Figure S1</a>). While the skeleton containing the phenoxyimidazoline and pyridine groups was computed by the two methods to have the same general shape (the dihedral angles α[N(1)-C(2)-C(3)-C(4)], β[C(4)-C(5)-O(6)-C(7)] and γ[C(5)-O(6)-C(7)-N(8)] were within 2–6°), the mutual orientation of the phenoxyamidine and sarcosine moieties was completely different. The B3LYP method predicted the most stable conformation in which these moieties are in the maximal extended position, while for the B97D structure, a bent molecule was found (the distance C(=O)O-H···N = 1.54 Å), stabilized by means of intramolecular hydrogen bonds formed by the acidic hydrogen of the sarcosine carboxyl and the basic nitrogen atom of the phenoxyamidine group. The amidine and phenyl groups of the phenoxyamidine moiety form a dihedral angle ζ[C(12)-C(13)-C(14)-N(15)] of about 21° (B3LYP) and 28° (B97D). The structural arrangement around the ether bond connecting the phenoxyamidine and pyridine groups was described completely differently by the B3LYP and B97D methods (the dihedral angle δ[N(8)-C(9)-O(10)-C(11)] of −19.4° (B3LYP) and −106° (B97D); <a href="#molecules-21-00185-t001" class="html-table">Table 1</a>). These large differences in dihedral angles obtained by two DFT methods could be partially explained by significant overestimation the dispersion in this system. The molecular geometry of hydrated fidexaban treated with the B3LYP functional changed only slightly (<a href="#molecules-21-00185-f004" class="html-fig">Figure 4</a>). However, the dramatic structural rearrangement of fidexaban upon hydration occurred with the B97D functional. The B97D optimized solvated fidexaban resembled the solvated structure of this molecule computed with B3LYP (<a href="#molecules-21-00185-t001" class="html-table">Table 1</a>). Accordingly, the environmental effect partially compensated overestimated dispersion interaction also manifested in the absence of the intramolecular C(=O)O-H···N interaction in the optimized structure (<a href="#molecules-21-00185-t001" class="html-table">Table 1</a>, <a href="#app1-molecules-21-00185" class="html-app">Figure S1</a>). An analysis of crystal structure of the fidexaban-fXa complex (pdf file 1FJS) shows that the phenoxyamidine group accommodates the polar S1 pocket and the hydrophobic part of the drug’s phenoxyimidazoline moiety is located at the hydrophobic S4 site. The final biologically active conformation of fidexaban is governed by a strong salt bridge of amidine group with Asp189 in the S1 pocket [<a href="#B22-molecules-21-00185" class="html-bibr">22</a>], which results in a large conformational change to the phenylamidine scaffold of this drug upon complexation with fXa (<a href="#molecules-21-00185-f004" class="html-fig">Figure 4</a>). The corresponding dihedral angles δ[N(8)-C(9)-O(10)-C(11)] and ε[C(9)-O(10)-C(11)-C(12)] are −19.6° and −56.8° for the complexed species and −106° and 9.6° for the isolated molecule, respectively (<a href="#molecules-21-00185-t001" class="html-table">Table 1</a>). The large conformational differences between conformations of unbound and bound fidexaban could be explained by the intermolecular interactions between fidexaban and receptor. The central pyridine ring represents a rigid scaffold which orients the phenoxyimidazoline moiety towards Trp215 in the S4 pocket, stabilized by an aromatic ring stacking interaction between the fidexaban and the corresponding aromatic amino acid of receptor. The biologically active conformation of fidexaban is less stable by 319 kJ/mol.</div><div class="html-fig-wrap" id="molecules-21-00185-f004">
  <div class='html-fig_img'>
    <div class="html-figpopup html-figpopup-link" href="#fig_body_display_molecules-21-00185-f004">
      <img alt="Molecules 21 00185 g004 1024" data-large="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g004-1024.png" data-original="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g004.png" src="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g004-1024.png" />
      <a class="html-expand html-figpopup" href="#fig_body_display_molecules-21-00185-f004"></a>
    </div>

  </div>
  <div class="html-fig_description">
    <b>Figure 4.</b>
      Molecular superimposition of the Becke3LYP optimized molecular structure of fidexaban (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="#006600" mathvariant="bold">green</mtext>
            </mrow>
          </semantics>
        </math>), in solution optimized fidexaban (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="red" mathvariant="bold">red</mtext>
            </mrow>
          </semantics>
        </math>) and fidexaban from the co-crystal with coagulation factor Xa, pdb.1FJS (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="blue" mathvariant="bold">blue</mtext>
            </mrow>
          </semantics>
        </math>). For simplicity the hydrogen atoms are omitted.
<!--     <p><a class="html-figpopup" href="#fig_body_display_molecules-21-00185-f004">
      Click here to enlarge figure
    </a></p> -->

  </div>
</div>
<div class="html-fig_show  mfp-hide" id ="fig_body_display_molecules-21-00185-f004" >
  <div class="html-caption" > <b>Figure 4.</b>
      Molecular superimposition of the Becke3LYP optimized molecular structure of fidexaban (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="#006600" mathvariant="bold">green</mtext>
            </mrow>
          </semantics>
        </math>), in solution optimized fidexaban (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="red" mathvariant="bold">red</mtext>
            </mrow>
          </semantics>
        </math>) and fidexaban from the co-crystal with coagulation factor Xa, pdb.1FJS (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="blue" mathvariant="bold">blue</mtext>
            </mrow>
          </semantics>
        </math>). For simplicity the hydrogen atoms are omitted.</div>
  <div class="html-img"><img alt="Molecules 21 00185 g004 1024" data-large="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g004-1024.png" data-original="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g004.png" src="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g004-1024.png" /></div>
</div></section><section id='sec2dot1dot4-molecules-21-00185' type=''><h4 class= data-nested='3'>  2.1.4. Darexaban</h4><div class='html-p'>Darexaban (<span class='html-italic'>N</span>-(3-hydroxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl)-4-methoxybenzamide) is a novel fXa inhibitor without an amidine moiety incorporated into previous fXa inhibitors like fidexaban, otamixaban and betrixaban [<a href="#B23-molecules-21-00185" class="html-bibr">23</a>]. Upon oral administration in humans, darexaban is well-absorbed from the gastrointestinal tract, with most of the absorbed drug rapidly metabolized to darexaban glucuronide (M1), the pharmacological activity of which is equipotent to unchanged darexaban [<a href="#B23-molecules-21-00185" class="html-bibr">23</a>]. Its development was discontinued in September 2011 [<a href="#B20-molecules-21-00185" class="html-bibr">20</a>]. Darexaban contains a central 1,2-phenylenediamide scaffold; the amide groups are for stereochemical reasons twisted out of the phenyl ring plane by about 42° and −55° (B3LYP, dihedral angles α[C(1)-C(2)-N(3)-C(4)] and ζ[C(2)-C(12)-N(13)-C(14)], <a href="#molecules-21-00185-t001" class="html-table">Table 1</a>), respectively. The 1,4-benzodiazepane moiety is perpendicularly oriented to the phenyl substituent, and together with 4-methoxybenzamide forms a typical U-shaped structure stabilized by means of OH···O=C and NH···O=C intramolecular hydrogen bonds among polar substituents on the central phenyl ring (<a href="#molecules-21-00185-t001" class="html-table">Table 1</a>, <a href="#app1-molecules-21-00185" class="html-app">Figure S1</a>). A different 3D structure resulted from the B97D calculations. The terminal 1,4-benzodiazepane and 4-methoxybenzamide groups were more twisted and closer to each other and stabilized via a OH···O=C hydrogen bond (<a href="#app1-molecules-21-00185" class="html-app">Figure S1</a>). The solvent effect treated within the conductor-like polarizable continuum model (CPCM) did not significantly change the 3D structure of the isolated molecule (<a href="#molecules-21-00185-t001" class="html-table">Table 1</a>).</div></section><section id='sec2dot1dot5-molecules-21-00185' type=''><h4 class= data-nested='3'>  2.1.5. Letaxaban</h4><div class='html-p'>Letaxaban (1-(1-{(2<span class='html-italic'>S</span>)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)tetrahydro-2(1<span class='html-italic'>H</span>)-pyrimidinone), also known as TAK-442, is a potent, selective, and orally active factor Xa inhibitor, and is a tetrahydropyrimidin-2(1<span class='html-italic'>H</span>)-one derivative [<a href="#B24-molecules-21-00185" class="html-bibr">24</a>]. Letaxaban was discontinued in May 2011 following disappointing phase II results [<a href="#B20-molecules-21-00185" class="html-bibr">20</a>]. The 3D molecular structure computed at the B3LYP level of theory of its biologically active (<span class='html-italic'>S</span>) enantiomer is shown in <a href="#app1-molecules-21-00185" class="html-app">Figure S1</a>. Both the B3LYP and G97D functionals predicted almost the same mutual structural arrangement of basic functional groups (<a href="#molecules-21-00185-t001" class="html-table">Table 1</a>). Letaxaban belongs to the relatively rigid fXa inhibitors, and its minimum energy conformer possesses the typical L-shape required for proper orientation of its terminal functional groups towards the receptor site. Regarding the isolated molecule, the hydrophobic 6-chloronaphthyl group and sulfonyl moiety are in a mutual <span class='html-italic'>anti</span> arrangement (dihedral angle α[C(1)-C(2)-S(3)-C(4)] is about 96–99°, <a href="#molecules-21-00185-t001" class="html-table">Table 1</a>), a stable conformation also found in structurally related aromatic sulfonamides [<a href="#B25-molecules-21-00185" class="html-bibr">25</a>,<a href="#B26-molecules-21-00185" class="html-bibr">26</a>], which orients this part of the drug perpendicularly to the rest of the molecule. The 6-chloronaphthyl group interacts by means of a hydrophobic interaction with the aromatic ring of Tyr228 in the S1 binding site. The 2-hydroxypropanoyl moiety exists in a stable periplanar conformation (the dihedral angles δ[S(3)-C(4)-C(5)-C(7)] and ε[C(4)-C(5)-C(7)-N(8)] are about −167° and 165°, respectively).</div><div class='html-p'>The synclinal orientation of the hydroxyl group towards sulfonyl group (the dihedral angle γ[S(3)-C(4)-C(5)-O(6)] is about 73°) ensures additional hydrogen-bonded interactions of letaxaban with the nitrogen atom of the main chain Gly216 of the fXa receptor. The tetrahydropyrimidinone group is in an anticlinal position with respect to the piperidinyl ring (dihedral angle η[C(10)-C(11)-N(12)-C(13)]; <a href="#molecules-21-00185-t001" class="html-table">Table 1</a>) and is involved in hydrophobic interaction with the aromatic rings of Tyr99, Phe174, and Trp215 located in the S4 site of the receptor [<a href="#B24-molecules-21-00185" class="html-bibr">24</a>]. The 3D geometry of letaxaban in water, computed with the polarizable continuum method using the CPCM model, did not appreciably differ from the geometries computed for isolated molecules (<a href="#molecules-21-00185-t001" class="html-table">Table 1</a>). The stable conformation letaxaban when bound at the fXa receptor (PDB file 3KL6) is close to the 3D structure of isolated drug and/or solvated conformer and only small changes in geometry upon complexation were observed (<a href="#molecules-21-00185-f005" class="html-fig">Figure 5</a>), and the biologically active conformer is 96 kJ/mol less stable than the unbound structure.</div><div class="html-fig-wrap" id="molecules-21-00185-f005">
  <div class='html-fig_img'>
    <div class="html-figpopup html-figpopup-link" href="#fig_body_display_molecules-21-00185-f005">
      <img alt="Molecules 21 00185 g005 1024" data-large="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g005-1024.png" data-original="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g005.png" src="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g005-1024.png" />
      <a class="html-expand html-figpopup" href="#fig_body_display_molecules-21-00185-f005"></a>
    </div>

  </div>
  <div class="html-fig_description">
    <b>Figure 5.</b>
      Molecular superimposition of the Becke3LYP optimized molecular structure of letaxaban (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="#006600" mathvariant="bold">green</mtext>
            </mrow>
          </semantics>
        </math>), in solution optimized letaxaban (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="red" mathvariant="bold">red</mtext>
            </mrow>
          </semantics>
        </math>) and letaxaban from the co-crystal with coagulation factor Xa, PDB.3KL6 (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="blue" mathvariant="bold">blue</mtext>
            </mrow>
          </semantics>
        </math>). For simplicity the hydrogen atoms are omitted.
<!--     <p><a class="html-figpopup" href="#fig_body_display_molecules-21-00185-f005">
      Click here to enlarge figure
    </a></p> -->

  </div>
</div>
<div class="html-fig_show  mfp-hide" id ="fig_body_display_molecules-21-00185-f005" >
  <div class="html-caption" > <b>Figure 5.</b>
      Molecular superimposition of the Becke3LYP optimized molecular structure of letaxaban (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="#006600" mathvariant="bold">green</mtext>
            </mrow>
          </semantics>
        </math>), in solution optimized letaxaban (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="red" mathvariant="bold">red</mtext>
            </mrow>
          </semantics>
        </math>) and letaxaban from the co-crystal with coagulation factor Xa, PDB.3KL6 (<math display='inline'>
          <semantics>
            <mrow>
              <mtext mathcolor="blue" mathvariant="bold">blue</mtext>
            </mrow>
          </semantics>
        </math>). For simplicity the hydrogen atoms are omitted.</div>
  <div class="html-img"><img alt="Molecules 21 00185 g005 1024" data-large="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g005-1024.png" data-original="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g005.png" src="/molecules/molecules-21-00185/article_deploy/html/images/molecules-21-00185-g005-1024.png" /></div>
</div></section><section id='sec2dot1dot6-molecules-21-00185' type=''><h4 class= data-nested='3'>  2.1.6. Tanogitran (Dual)</h4><div class='html-p'>Tanogitran (<span class='html-italic'>N</span>-[(2<span class='html-italic'>R</span>)-2-(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1<span class='html-italic'>H</span>-benzimidazol-5-yl)-1-oxo-1-(1-pyrrolidinyl)-2-propanyl]glycine) is a dual inhibitor of thrombin and factor Xa. Tanogitran (FXa <span class='html-italic'>K</span><sub>i</sub> = 26 nM, thrombin <span class='html-italic'>K</span><sub>i</sub> = 2.7 nM [<a href="#B4-molecules-21-00185" class="html-bibr">4</a>,<a href="#B27-molecules-21-00185" class="html-bibr">27</a>] is a reversible dual inhibitor evaluated in phase II clinical trial studies in human model of endotoxin-induced coagulation [<a href="#B27-molecules-21-00185" class="html-bibr">27</a>]. Its discovery is closely related to the development of dabigatran, a single direct oral thrombin inhibitor [<a href="#B7-molecules-21-00185" class="html-bibr">7</a>]. Tanogitran, like dabigatran, contains a central substituted benzimidazole skeleton, an amino group of the linker between phenylamidine and benzimidazole rings and, at the opposite end of a molecule, a 5-propyl linker carrying aliphatic substituent glycine and pyrolidinne groups. In the absence of experimental structural data, the initial geometry of tanogitran was constructed on the basis of our previous studies of its predecessor, dabigatran [<a href="#B12-molecules-21-00185" class="html-bibr">12</a>]. In the thermodynamically stable structure of the isolated molecule, the phenylamidine and pyrrolidinyl end groups are perpendicularly arranged to the plane of the central benzimidazole scaffold and oriented <span class='html-italic'>synperiplanar</span>. The polar glycine part is also almost perpendicular to the benzimidazole scaffold and oppositely oriented to the pyrrolidinyl substituent (<a href="#app1-molecules-21-00185" class="html-app">Figure S1</a>). The amidine group of the phenylamidine substituent is twisted out of the benzene ring by about −20° (dihedral angle α[N(1)-C(2)-C(3)-C(4)], <a href="#molecules-21-00185-f001" class="html-fig">Figure 1</a>). The methylamino group of the linker between phenylamidine and benzimidazole is antiperiplanar to the aromatic ring (dihedral angle β[ C(5)-C(6)-N(7)-C(8)] = 165.5°, B3LYP calculation). However, the conformational structure of the molecular fragment connected by this spacer was described differently by the two DFT methods (dihedral angle γ[C(6)-N(7)-C(8)-C(9)] is about 79° (B3LYP) and 49° (B97D)). Thus, in the B97D optimized geometry, the phenylamidine and pyrrolidinyl substituents were more closely oriented to each other (<a href="#app1-molecules-21-00185" class="html-app">Figure S1</a>). The solvent effect did not appreciably change the general shape of the molecule (<a href="#molecules-21-00185-t001" class="html-table">Table 1</a>).</div></section><section id='sec2dot1dot7-molecules-21-00185' type=''><h4 class= data-nested='3'>  2.1.7. SAR107375 (Dual)</h4><div class='html-p'>SAR107375 (5-chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide) is a novel dual inhibitor discovered by Meneyrol <span class='html-italic'>et al.</span> [<a href="#B28-molecules-21-00185" class="html-bibr">28</a>]. The 3D molecular structure optimized at the B3LYP level of theory represents a sandwich arrangement of the basic 4-methylpiperazine and benzenesulfonyl amino moieties connected via an oxopropyl amide linker (<a href="#app1-molecules-21-00185" class="html-app">Figure S1</a>). A third substituent, chlorothiophene carboxamide, is oriented away from the molecular scaffold and forms a strong interaction in the S1 pocket of the receptor. The sulfonamide linker is in a <span class='html-italic'>gauche</span> arrangement between the aromatic ring and an S-N bond (dihedral angle ξ[N(11)-S(12)-C(13)-C(14)] is about 60°). The N-H and S=O groups are also in a mutual <span class='html-italic'>gauche</span> conformation (dihedral angle μ[C(7)-N(11)-S(12)-C(13)], <a href="#molecules-21-00185-t001" class="html-table">Table 1</a>). The unique conformation of the oxopropylamide and sulfonamide moieties (dihedral angle σ[N(9)-C(8)-C(7)-N(11)]) is stabilized via hydrogen bond interactions of the N-H···O=C type in an <span class='html-italic'>antiperiplanar</span> arrangement (<a href="#molecules-21-00185-t001" class="html-table">Table 1</a>, <a href="#app1-molecules-21-00185" class="html-app">Figure S1</a>). The oxopyrrolidine end group and aromatic ring are in a mutual <span class='html-italic'>anticlinal</span> position (dihedral angle ρ[C(14)-C(15)-N(16)-C(17)]; <a href="#molecules-21-00185-t001" class="html-table">Table 1</a>). Almost the same equilibrium conformation of SAR107375 resulted from the geometry optimization by means of the B97D functional (<a href="#molecules-21-00185-t001" class="html-table">Table 1</a>). The equilibrium structure of the thiophene amide moiety is stabilized by means of non-bonded interaction between thiophene sulfur and neighboring oxygen of 2-amide group (<a href="#app1-molecules-21-00185" class="html-app">Figure S1</a>). In this molecule, the computed distance (about 2.95 Å) between non-bonded S···O atoms of the carbonyl amido group and the thiophene ring is clearly shorter than the sum of the corresponding van der Waals radii for oxygen and sulfur atoms (3.32 Å) [<a href="#B29-molecules-21-00185" class="html-bibr">29</a>]. This effect has been observed in a large number of organosulfur compounds controlling the conformation of small and large molecules [<a href="#B30-molecules-21-00185" class="html-bibr">30</a>,<a href="#B31-molecules-21-00185" class="html-bibr">31</a>].</div></section></section><section id='sec2dot2-molecules-21-00185' type=''><h4 class=html-italic data-nested='2'>  2.2. Dissociation Constants</h4><div class='html-p'>Several potent fXa inhibitors entered into clinical trials contain an acidic or a basic center, which may be ionized and/or protonated at physiological pH. Dissociation of a drug plays important part in both the partition and the binding of such drugs with their target enzyme. <a href="#molecules-21-00185-t003" class="html-table">Table 3</a> contains the macroscopic p<span class='html-italic'>K</span>a values of the studied anticoagulants. The p<span class='html-italic'>K</span>a values in the condensed phase (water) were calculated using program SPARC [<a href="#B32-molecules-21-00185" class="html-bibr">32</a>,<a href="#B33-molecules-21-00185" class="html-bibr">33</a>]. Eribaxaban, and letaxaban are present in neutral undissociated form at pH 7.4. Edoxaban contains a basic N-5 nitrogen atom of 5-methylthiazolopyridine moiety and is partly protonated at pH 7.4. The structurally related 1,4-benzodiazepane moiety of darexaban possesses highly-basic N-4 nitrogen atom (p<span class='html-italic'>K</span>a = 8.11), which is highly protonated at physiological pH. The dual inhibitor SAR107375 contains a basic methylpiperazine moiety with the N-4 nitrogen primary protonation site. The N-H group of the sulfonamide moiety is a weak acid (p<span class='html-italic'>K</span>a = 8.35) slightly ionized at physiological p<span class='html-italic'>H</span>. The direct fXa inhibitor fidexaban and dual fXa and thrombin inhibitor tanogitran possess both acidic (carboxyl) and basic (amidine) functionality. Both moieties are completely ionised at physiological pH and may exist, like the direct thrombin inhibitor dabigatran [<a href="#B12-molecules-21-00185" class="html-bibr">12</a>], as zwitterionic structures. Clinically approved direct fXa inhibitor edoxaban exists as partially dissociated molecules at blood pH. Lipid solubility is the rate limiting factor for drugs that are neutral or mainly undissociated at pH 7.4, thus the investigation into the lipophilicity and water-solubility of fXa and fIIa inhibitors is of primary importance to facilitate the partitioning of the drug in the lipid biomembrane and into the systemic circulation [<a href="#B34-molecules-21-00185" class="html-bibr">34</a>].</div><div class="html-table-wrap" id="molecules-21-00185-t003">
  <div class="html-table_wrap_td" >
    <div class="html-tablepopup html-tablepopup-link" href='#table_body_display_molecules-21-00185-t003'>
        <img alt="Table" src="http://img.mdpi.org/img/table.png" />
       <a class="html-expand html-tablepopup" href="#table_body_display_molecules-21-00185-t003"></a>
    </div>

  </div>
  <div class="html-table_wrap_discription">
    <b>Table 3.</b>
    The p<span class='html-italic'>K</span>a values (at 25° C) of the anticoagulants investigated (SPARC/p<span class='html-italic'>K</span>a).
  </div>
</div>
<div class="html-table_show  mfp-hide " id ="table_body_display_molecules-21-00185-t003" >
  
  <table >
    <caption ><b>Table 3.</b>
    The p<span class='html-italic'>K</span>a values (at 25° C) of the anticoagulants investigated (SPARC/p<span class='html-italic'>K</span>a).</caption>
    <thead  ><tr  ><th rowspan='2' align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >Drug</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >p<span class='html-italic'>K</span>a</th><th colspan='2' align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >p<span class='html-italic'>K</span>a</th><th colspan='2' align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >% Ionized Form</th></tr><tr  ><th align='center' valign='middle' style='border-bottom:solid thin' >Exp.</th><th align='center' valign='middle' style='border-bottom:solid thin' >Acid Function <sup>a</sup></th><th align='center' valign='middle' style='border-bottom:solid thin' >Basic Function <sup>b</sup></th><th align='center' valign='middle' style='border-bottom:solid thin' >Acid Function</th><th align='center' valign='middle' style='border-bottom:solid thin' >Basic Function</th></tr></thead><tbody  ><tr  ><td align='center' valign='middle' >Edoxaban</td><td align='center' valign='middle' >6.7 (FDA label) <sup>c</sup></td><td align='center' valign='middle' >11.08</td><td align='center' valign='middle' >7.23</td><td align='center' valign='middle' >0</td><td align='center' valign='middle' >40</td></tr><tr  ><td align='center' valign='middle' >Eribaxaban</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >9.04</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >2</td><td align='center' valign='middle' > </td></tr><tr  ><td align='center' valign='middle' >Fidexaban</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >3.54</td><td align='center' valign='middle' >12.28</td><td align='center' valign='middle' >100</td><td align='center' valign='middle' >100</td></tr><tr  ><td align='center' valign='middle' >Darexaban</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >8.76</td><td align='center' valign='middle' >8.11</td><td align='center' valign='middle' >4</td><td align='center' valign='middle' >83</td></tr><tr  ><td align='center' valign='middle' >Letaxaban</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >12.93</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >0</td><td align='center' valign='middle' > </td></tr><tr  ><td align='center' valign='middle' >Tanogitran</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >1.98</td><td align='center' valign='middle' >11.53</td><td align='center' valign='middle' >100</td><td align='center' valign='middle' >100</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' >SAR107375</td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' >8.35</td><td align='center' valign='middle' style='border-bottom:solid thin' >6.52</td><td align='center' valign='middle' style='border-bottom:solid thin' >10</td><td align='center' valign='middle' style='border-bottom:solid thin' >11</td></tr></tbody>
  </table>
  <div class='html-table_foot html-p'><div class='html-p' style='text-indent:0em;'><span class='html-fn-content'><sup>a</sup> most acidic; <sup>b</sup> most basic; <sup>c</sup> more details are in Drug Bank [<a href="#B35-molecules-21-00185" class="html-bibr">35</a>].</span></div></div>
</div></section><section id='sec2dot3-molecules-21-00185' type=''><h4 class=html-italic data-nested='2'>  2.3. Lipophilicity and Solubility</h4><div class='html-p'>The direct fXa and fIIa inhibitors, as well as their dual derivatives, were designed on the basis of knowing the basic molecular features of the target proteins. The two most important binding sites (S1 and S4) are hydrophobic in nature (S1 is a deep cleft and S4 is a strongly hydrophobic pocket), thus it is important to know the lipophilicity of designed inhibitors. The calculated log <span class='html-italic'>P</span> and log <span class='html-italic'>S</span> values using the ALOGPS 2.1 program are shown in <a href="#molecules-21-00185-t004" class="html-table">Table 4</a>. The lipophilicity predictions within this program are based on the use of E-state indicies and on the associative neural network approach [<a href="#B36-molecules-21-00185" class="html-bibr">36</a>]. As it is shown previously [<a href="#B11-molecules-21-00185" class="html-bibr">11</a>,<a href="#B12-molecules-21-00185" class="html-bibr">12</a>], this method performs quite well by predictions of experimentally known log <span class='html-italic'>P</span> values of anticoagulants. A trend in calculated compound lipophilicity was observed: it was lowest for the dual inhibitors tanogitran and SAR107375 and increased for the clinically approved fXa inhibitor edoxaban. The experimental direct fXa inhibitors eribaxaban, fidexaban, and darexaban possess greater lipophilicity. However, their development was later disrupted. Fidexaban, darexaban, and tanogitran are almost completely ionized at pH 7.4 (<a href="#molecules-21-00185-t003" class="html-table">Table 3</a>). For drugs with ionizable functional groups, the effective lipophilicity is depends on pH, and the distribution coefficient log <span class='html-italic'>D</span> will be different from log <span class='html-italic'>P</span>. The log <span class='html-italic'>D</span> values, calculated from the predicted log <span class='html-italic'>P</span> (ALOGP method) and p<span class='html-italic'>K</span>a (Sparc) using the equation log <span class='html-italic'>D</span> = log <span class='html-italic'>P</span> − log (1 + 10<sup>pH−p<span class='html-italic'>K</span>a</sup>) for acids and log <span class='html-italic'>D</span> = log <span class='html-italic'>P</span> − log (1 + 10<sup>p<span class='html-italic'>K</span>a−pH</sup>) for bases [<a href="#B37-molecules-21-00185" class="html-bibr">37</a>], are also presented in <a href="#molecules-21-00185-t004" class="html-table">Table 4</a>. The calculated log<span class='html-italic'>D</span><sub>7.4</sub> values for the ionizable drugs were substantially lower. Aqueous solubility <span class='html-italic'>S</span> is one of tne most important facors, which has impact on pharmacokinetic properties of oral drugs. The computed log <span class='html-italic'>S</span> (the intrinsic solubility in the neutral state), is a measure of a drug’s solubility (<span class='html-italic'>S</span>). The studied anticoagulants were slightly soluble in water; nevertheless their computed solubility, between 7 and 200 mg/L, is enough for fast absorption (<a href="#molecules-21-00185-t004" class="html-table">Table 4</a> and <a href="#molecules-21-00185-t005" class="html-table">Table 5</a>). Fidexaban and tanogitran contain polar benzamidine and a carboxylate groups and in aqueous solution exhibit amphoteric properties. Because of their zwitterionic character, and log <span class='html-italic'>D</span><sub>7.4</sub> = −0.79 and −3.84, they have no appreciable bioavailability after oral application.</div><div class="html-table-wrap" id="molecules-21-00185-t004">
  <div class="html-table_wrap_td" >
    <div class="html-tablepopup html-tablepopup-link" href='#table_body_display_molecules-21-00185-t004'>
        <img alt="Table" src="http://img.mdpi.org/img/table.png" />
       <a class="html-expand html-tablepopup" href="#table_body_display_molecules-21-00185-t004"></a>
    </div>

  </div>
  <div class="html-table_wrap_discription">
    <b>Table 4.</b>
    Calculated lipophilicity (log <span class='html-italic'>P</span>) and solubility (log <span class='html-italic'>S</span>) of the anticoagulants studied.
  </div>
</div>
<div class="html-table_show  mfp-hide " id ="table_body_display_molecules-21-00185-t004" >
  
  <table >
    <caption ><b>Table 4.</b>
    Calculated lipophilicity (log <span class='html-italic'>P</span>) and solubility (log <span class='html-italic'>S</span>) of the anticoagulants studied.</caption>
    <thead  ><tr  ><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >Drug</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >ALOGPS</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >Log <span class='html-italic'>D</span>, (pH = 7.4)</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >ALOGPS, Solubility</th></tr></thead><tbody  ><tr  ><td align='center' valign='middle' >Edoxaban</td><td align='center' valign='middle' >1.61</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−4.68 (11.4 mg/L)</td></tr><tr  ><td align='center' valign='middle' >Eribaxaban</td><td align='center' valign='middle' >3.35</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−4.83 (7.2 mg/L)</td></tr><tr  ><td align='center' valign='middle' >Fidexaban</td><td align='center' valign='middle' >3.07</td><td align='center' valign='middle' >−0.79</td><td align='center' valign='middle' >−4.34 (24.2 mg/L)</td></tr><tr  ><td align='center' valign='middle' >Darexaban</td><td align='center' valign='middle' >4.03</td><td align='center' valign='middle' >3.24</td><td align='center' valign='middle' >−4.21 (29.1 mg/L)</td></tr><tr  ><td align='center' valign='middle' >Letaxaban</td><td align='center' valign='middle' >1.55</td><td align='center' valign='middle' > </td><td align='center' valign='middle' >−3.34 (0.2 g/L)</td></tr><tr  ><td align='center' valign='middle' >Tanogitran</td><td align='center' valign='middle' >1.58</td><td align='center' valign='middle' >−3.84</td><td align='center' valign='middle' >−3.54 (0.14 g/L)</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' >SAR107375</td><td align='center' valign='middle' style='border-bottom:solid thin' >1.15</td><td align='center' valign='middle' style='border-bottom:solid thin' > </td><td align='center' valign='middle' style='border-bottom:solid thin' >−4.42 (21.4 mg/L)</td></tr></tbody>
  </table>
  
</div><div class="html-table-wrap" id="molecules-21-00185-t005">
  <div class="html-table_wrap_td" >
    <div class="html-tablepopup html-tablepopup-link" href='#table_body_display_molecules-21-00185-t005'>
        <img alt="Table" src="http://img.mdpi.org/img/table.png" />
       <a class="html-expand html-tablepopup" href="#table_body_display_molecules-21-00185-t005"></a>
    </div>

  </div>
  <div class="html-table_wrap_discription">
    <b>Table 5.</b>
    Calculated absorption (%ABS), polar surface area (PSA) and Lipinski parameters of the anticoagulants studied.
  </div>
</div>
<div class="html-table_show  mfp-hide " id ="table_body_display_molecules-21-00185-t005" >
  
  <table >
    <caption ><b>Table 5.</b>
    Calculated absorption (%ABS), polar surface area (PSA) and Lipinski parameters of the anticoagulants studied.</caption>
    <thead  ><tr  ><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >Drug</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >%ABS</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >Volume</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >PSA</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >NROTB</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' ><span class='html-italic'>n</span> ON Acceptors</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' ><span class='html-italic'>n</span> OHNH Donors</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >Formula Weight</th></tr></thead><tbody  ><tr  ><td align='center' valign='middle' >Edoxaban</td><td align='center' valign='middle' >61.9</td><td align='center' valign='middle' >469.39</td><td align='center' valign='middle' >136.62</td><td align='center' valign='middle' >6</td><td align='center' valign='middle' >11 <sup>a</sup></td><td align='center' valign='middle' >3</td><td align='center' valign='middle' >548.07 <sup>a</sup></td></tr><tr  ><td align='center' valign='middle' >Eribaxaban</td><td align='center' valign='middle' >77.0</td><td align='center' valign='middle' >407.20</td><td align='center' valign='middle' >92.67</td><td align='center' valign='middle' >5</td><td align='center' valign='middle' >8</td><td align='center' valign='middle' >2</td><td align='center' valign='middle' >484.91</td></tr><tr  ><td align='center' valign='middle' >Fidexaban</td><td align='center' valign='middle' >54.6</td><td align='center' valign='middle' >440.66</td><td align='center' valign='middle' >157.60</td><td align='center' valign='middle' >9</td><td align='center' valign='middle' >11 <sup>a</sup></td><td align='center' valign='middle' >5</td><td align='center' valign='middle' >526.55 <sup>a</sup></td></tr><tr  ><td align='center' valign='middle' >Darexaban</td><td align='center' valign='middle' >76.5</td><td align='center' valign='middle' >438.49</td><td align='center' valign='middle' >94.13</td><td align='center' valign='middle' >6</td><td align='center' valign='middle' >8</td><td align='center' valign='middle' >3</td><td align='center' valign='middle' >474.61</td></tr><tr  ><td align='center' valign='middle' >Letaxaban</td><td align='center' valign='middle' >72.1</td><td align='center' valign='middle' >403.34</td><td align='center' valign='middle' >107.02</td><td align='center' valign='middle' >5</td><td align='center' valign='middle' >8</td><td align='center' valign='middle' >2</td><td align='center' valign='middle' >479.99</td></tr><tr  ><td align='center' valign='middle' >Tanogitran</td><td align='center' valign='middle' >57.5</td><td align='center' valign='middle' >437.41</td><td align='center' valign='middle' >149.36</td><td align='center' valign='middle' >9</td><td align='center' valign='middle' >10</td><td align='center' valign='middle' >6 <sup>a</sup></td><td align='center' valign='middle' >477.57</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' >SAR107375</td><td align='center' valign='middle' style='border-bottom:solid thin' >67.9</td><td align='center' valign='middle' style='border-bottom:solid thin' >473.92</td><td align='center' valign='middle' style='border-bottom:solid thin' >119.12</td><td align='center' valign='middle' style='border-bottom:solid thin' >8</td><td align='center' valign='middle' style='border-bottom:solid thin' >10</td><td align='center' valign='middle' style='border-bottom:solid thin' >2</td><td align='center' valign='middle' style='border-bottom:solid thin' >568.18 <sup>a</sup></td></tr></tbody>
  </table>
  <div class='html-table_foot html-p'><div class='html-p' style='text-indent:0em;'><span class='html-fn-content'><sup>a</sup> Violation of the Rule of Five (Mw <span class='html-italic'>&gt;</span> 500).</span></div></div>
</div></section><section id='sec2dot4-molecules-21-00185' type=''><h4 class=html-italic data-nested='2'>  2.4. Absorption, Polar Surface Area, and “Rule of Five” Properties</h4><div class='html-p'>The studied anticoagulants were developed for oral administration, which is associated with high patient compliance. However, low intestinal absorption of designed anticoagulants may limit their clinical application [<a href="#B38-molecules-21-00185" class="html-bibr">38</a>]. Properties of drugs, such as membrane permeability or bioavailability, have often been related to molecular parameters such as molecular weight (<span class='html-italic'>MW</span>), lipophilicity (log <span class='html-italic'>P</span>), or counts of hydrogen bond acceptors and donors in a molecule. Orally absorbed novel anticoagulants tend to obey “Rule of Five” properties designed by Lipinski <span class='html-italic'>et al.</span> [<a href="#B39-molecules-21-00185" class="html-bibr">39</a>]. This guideline is frequently used as a filter for drug-like properties. The calculated molecular descriptors (percentages of absorption (%ABS), molecular polar surface areas (PSA) and Lipinski parameters) are shown in <a href="#molecules-21-00185-t005" class="html-table">Table 5</a>. The magnitude of absorption is expressed by the percentage of absorption, which was evaluated according to the expression: %ABS = 109 − 0.345 PSA [<a href="#B40-molecules-21-00185" class="html-bibr">40</a>]. The PSA was calculated by the fragment-based method of Ertl and coworkers [<a href="#B41-molecules-21-00185" class="html-bibr">41</a>]. Edoxaban, fidexaban, and SAR107375 violated the “rule of five” (the molecular weight is too high), tanogitran, edoxaban and fidexaban also exhibited hydrogen bonding capacity over the limit, which is closely related to their highly polar character expressed by the large polar surface area of the studied drugs (<a href="#molecules-21-00185-t005" class="html-table">Table 5</a>). Fidexaban and tanogitran contain the highly basic arginine mimetic amidine group as the P1 moiety, which contributes to their poor oral bioavailability (<a href="#molecules-21-00185-t005" class="html-table">Table 5</a>). For the dual inhibitors tanogitran and SAR107375, the higher number of rotatable bonds in comparison with the clinically useful fXa inhibitors apixaban and rivaroxaban [<a href="#B11-molecules-21-00185" class="html-bibr">11</a>] impart higher conformational flexibility, enabling their interaction at the fXa and thrombin interaction sites in different conformations. Edoxaban, with a large polar surface area (136.62), may have worse absorption in comparison with rivaroxaban and apixaban [<a href="#B11-molecules-21-00185" class="html-bibr">11</a>]. Despite tremendous efforts connected with their discovery, the clinical development of eribaxaban, fidexaban, darexaban, and letaxaban has recently been halted [<a href="#B20-molecules-21-00185" class="html-bibr">20</a>,<a href="#B42-molecules-21-00185" class="html-bibr">42</a>]. The direct thrombin and fXa inhibitor tanogitran is a very flexible molecule with high total number of proton acceptor and proton donor groups (16), high PSA (149) and low absorption (<a href="#molecules-21-00185-t005" class="html-table">Table 5</a>). It contains, like the direct thrombin inhibitor dabigatran [<a href="#B12-molecules-21-00185" class="html-bibr">12</a>], ionizable acidic and basic functional groups, and under physiological conditions is present in the form of a charged species. Ionization of acidic or basic groups and the high PSA of tanogitran are not compatible with its oral application and tanogitran is not orally bioavailable. The dual inhibitor SAR107375 represents an improvement in structural, physicochemical and pharmacokinetic characteristics over tanogitran. At blood p<span class='html-italic'>H</span>, SAR107375 predominantly exists in neutral form (<a href="#molecules-21-00185-t003" class="html-table">Table 3</a>). In contrast to tanogitran, it is better absorbed and more lipophilic and active after oral application (<a href="#molecules-21-00185-t005" class="html-table">Table 5</a>).</div></section><section id='sec2dot5-molecules-21-00185' type=''><h4 class=html-italic data-nested='2'>  2.5. Selection Criteria for Drug-Like Properties of fXa Inhibitors</h4><div class='html-p'>Extensive screening programs in medicinal chemistry offered large number of structurally different and novel direct fXa inhibitors with biochemical activity in nano molar range. However, the discovery of a clinically useful fXa inhibitor is a very difficult task because different physicochemical properties are needed for either the interaction of an inhibitor to the active site of fXa or its absorption from the gastrointestinal tract. <a href="#molecules-21-00185-t006" class="html-table">Table 6</a> includes important molecular descriptors and measured binding affinities of 11 fXa inhibitors entered various stages of clinical trials. This Table includes two parenteral agents DX9065a and otamixaban, as well as, several orally active direct FXa inhibitors. </div><div class="html-table-wrap" id="molecules-21-00185-t006">
  <div class="html-table_wrap_td" >
    <div class="html-tablepopup html-tablepopup-link" href='#table_body_display_molecules-21-00185-t006'>
        <img alt="Table" src="http://img.mdpi.org/img/table.png" />
       <a class="html-expand html-tablepopup" href="#table_body_display_molecules-21-00185-t006"></a>
    </div>

  </div>
  <div class="html-table_wrap_discription">
    <b>Table 6.</b>
    Calculated molecular descriptors and experimental biochemical activity (<span class='html-italic'>K</span>i) of the novel anticoagulants.
  </div>
</div>
<div class="html-table_show  mfp-hide " id ="table_body_display_molecules-21-00185-t006" >
  
  <table >
    <caption ><b>Table 6.</b>
    Calculated molecular descriptors and experimental biochemical activity (<span class='html-italic'>K</span>i) of the novel anticoagulants.</caption>
    <thead  ><tr  ><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >Drug</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >%ABS</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >Volume Å<sup>3</sup></th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >PSA Å<sup>2</sup></th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >Clog <span class='html-italic'>S</span></th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >Clog <span class='html-italic'>P</span></th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >Formula Weight, Da</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' ><span class='html-italic'>K</span>i <sup>b</sup>, nmol/L</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >Bioavailability <sup>c</sup> %</th></tr></thead><tbody  ><tr  ><td align='center' valign='middle' >Rivaroxaban <sup>a</sup></td><td align='center' valign='middle' >77.8</td><td align='center' valign='middle' >351.74</td><td align='center' valign='middle' >88.18</td><td align='center' valign='middle' >−4.64</td><td align='center' valign='middle' >1.74</td><td align='center' valign='middle' >435.89</td><td align='center' valign='middle' >0.4</td><td align='center' valign='middle' >80</td></tr><tr  ><td align='center' valign='middle' >Apixaban <sup>a</sup></td><td align='center' valign='middle' >69.8</td><td align='center' valign='middle' >406.55</td><td align='center' valign='middle' >110.77</td><td align='center' valign='middle' >−3.83</td><td align='center' valign='middle' >2.23</td><td align='center' valign='middle' >459.51</td><td align='center' valign='middle' >0.08</td><td align='center' valign='middle' >50</td></tr><tr  ><td align='center' valign='middle' >Otamixaban <sup>a</sup></td><td align='center' valign='middle' >62.7</td><td align='center' valign='middle' >407.73</td><td align='center' valign='middle' >130.73</td><td align='center' valign='middle' >−5.35</td><td align='center' valign='middle' >2.12</td><td align='center' valign='middle' >446.51</td><td align='center' valign='middle' >0.4</td><td align='center' valign='middle' > </td></tr><tr  ><td align='center' valign='middle' >Betrixaban <b><sup>a</sup></b></td><td align='center' valign='middle' >70.1</td><td align='center' valign='middle' >392.76</td><td align='center' valign='middle' >107.41</td><td align='center' valign='middle' >−4.44</td><td align='center' valign='middle' >2.86</td><td align='center' valign='middle' >451.91</td><td align='center' valign='middle' >0.117</td><td align='center' valign='middle' >47</td></tr><tr  ><td align='center' valign='middle' >Razaxaban <sup>a</sup></td><td align='center' valign='middle' >66.5</td><td align='center' valign='middle' >423.70</td><td align='center' valign='middle' >120.04</td><td align='center' valign='middle' >−4.07</td><td align='center' valign='middle' >3.90</td><td align='center' valign='middle' >528.47 (viol.)</td><td align='center' valign='middle' >0.19</td><td align='center' valign='middle' > </td></tr><tr  ><td align='center' valign='middle' >DX-9065a <sup>a</sup></td><td align='center' valign='middle' >65.3</td><td align='center' valign='middle' >410.68</td><td align='center' valign='middle' >123.50</td><td align='center' valign='middle' >−4.49</td><td align='center' valign='middle' >2.61</td><td align='center' valign='middle' >444.53</td><td align='center' valign='middle' >41</td><td align='center' valign='middle' >3</td></tr><tr  ><td align='center' valign='middle' >Edoxaban</td><td align='center' valign='middle' >61.9</td><td align='center' valign='middle' >469.39</td><td align='center' valign='middle' >136.62</td><td align='center' valign='middle' >−4.68</td><td align='center' valign='middle' >1.61</td><td align='center' valign='middle' >548.07 (viol.)</td><td align='center' valign='middle' >0.56</td><td align='center' valign='middle' >62</td></tr><tr  ><td align='center' valign='middle' >Eribaxaban</td><td align='center' valign='middle' >77.0</td><td align='center' valign='middle' >407.20</td><td align='center' valign='middle' >92.67</td><td align='center' valign='middle' >−4.83</td><td align='center' valign='middle' >3.35</td><td align='center' valign='middle' >484.91</td><td align='center' valign='middle' >0.32</td><td align='center' valign='middle' > </td></tr><tr  ><td align='center' valign='middle' >Fidexaban</td><td align='center' valign='middle' >54.6</td><td align='center' valign='middle' >440.66</td><td align='center' valign='middle' >157.60</td><td align='center' valign='middle' >−4.34</td><td align='center' valign='middle' >3.07</td><td align='center' valign='middle' >526.55 (viol)</td><td align='center' valign='middle' >0.11</td><td align='center' valign='middle' > </td></tr><tr  ><td align='center' valign='middle' >Darexaban</td><td align='center' valign='middle' >76.5</td><td align='center' valign='middle' >438.49</td><td align='center' valign='middle' >94.13</td><td align='center' valign='middle' >−4.21</td><td align='center' valign='middle' >4.03</td><td align='center' valign='middle' >474.61</td><td align='center' valign='middle' >31</td><td align='center' valign='middle' > </td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' >Letaxaban</td><td align='center' valign='middle' style='border-bottom:solid thin' >72.1</td><td align='center' valign='middle' style='border-bottom:solid thin' >403.34</td><td align='center' valign='middle' style='border-bottom:solid thin' >107.02</td><td align='center' valign='middle' style='border-bottom:solid thin' >−3.34</td><td align='center' valign='middle' style='border-bottom:solid thin' >1.55</td><td align='center' valign='middle' style='border-bottom:solid thin' >479.99</td><td align='center' valign='middle' style='border-bottom:solid thin' >1.8</td><td align='center' valign='middle' style='border-bottom:solid thin' >50</td></tr></tbody>
  </table>
  <div class='html-table_foot html-p'><div class='html-p' style='text-indent:0em;'><span class='html-fn-content'><sup>a</sup> Reference [<a href="#B11-molecules-21-00185" class="html-bibr">11</a>]; <sup>b</sup> BindingDB database [<a href="#B43-molecules-21-00185" class="html-bibr">43</a>] and PDBbind-CN Database [<a href="#B44-molecules-21-00185" class="html-bibr">44</a>]; <sup>c</sup> Experimental bioavailability, references [<a href="#B45-molecules-21-00185" class="html-bibr">45</a>,<a href="#B46-molecules-21-00185" class="html-bibr">46</a>,<a href="#B47-molecules-21-00185" class="html-bibr">47</a>].</span></div></div>
</div><div class='html-p'>Three inhibitors approved for clinical use (apixaban, rivaroxaban and edoxaban) exhibit different physicochemical characteristics and also different absorption. The experimental bioavailability for oral drugs is different, but very high [<a href="#B45-molecules-21-00185" class="html-bibr">45</a>,<a href="#B46-molecules-21-00185" class="html-bibr">46</a>,<a href="#B47-molecules-21-00185" class="html-bibr">47</a>]. Within the limits of the examined property space, and with the exception of edoxaban, the percentage of experimental bioavailability seems to somehow correlate with calculated absorption (%ABS, <a href="#molecules-21-00185-t006" class="html-table">Table 6</a>). Computed molecular descriptors of these drugs were also used to determine selection criteria for drug-likeness of compounds (<a href="#molecules-21-00185-t007" class="html-table">Table 7</a>). Molecular weight, lipophilicity and solubility, together with the conformational structure discussed in the <a href="#sec2dot1-molecules-21-00185" class="html-sec">Section 2.1</a>, represent important physicochemical properties of drug-like fXa inhibitors. The inflated size of molecules results in molecular weight frequently violating the “rule of five”. The lipophilicity within a range of log <span class='html-italic'>P</span> between 1 and 4, and solubility log <span class='html-italic'>S</span> between −3 and −5, to ensure optimal physicochemical properties [<a href="#B48-molecules-21-00185" class="html-bibr">48</a>,<a href="#B49-molecules-21-00185" class="html-bibr">49</a>], and correspond well to the absence of importance of the hydrophobic effect determined from QSAR studies [<a href="#B49-molecules-21-00185" class="html-bibr">49</a>]. Polar surface area, owing to a structurally heterogeneous character of inhibitors, is from relatively large interval of values (<a href="#molecules-21-00185-t007" class="html-table">Table 7</a>). Drugs like rivaroxaban, apixaban, darexaban, eribaxan, letaxaban and betrixaban with lowest PSA values exhibit largest absorption.</div><div class="html-table-wrap" id="molecules-21-00185-t007">
  <div class="html-table_wrap_td" >
    <div class="html-tablepopup html-tablepopup-link" href='#table_body_display_molecules-21-00185-t007'>
        <img alt="Table" src="http://img.mdpi.org/img/table.png" />
       <a class="html-expand html-tablepopup" href="#table_body_display_molecules-21-00185-t007"></a>
    </div>

  </div>
  <div class="html-table_wrap_discription">
    <b>Table 7.</b>
    Drug-like properties of the novel direct fxa inhibitors.
  </div>
</div>
<div class="html-table_show  mfp-hide " id ="table_body_display_molecules-21-00185-t007" >
  
  <table >
    <caption ><b>Table 7.</b>
    Drug-like properties of the novel direct fxa inhibitors.</caption>
    <tbody  ><tr  ><td align='left' valign='middle' style='border-top:solid thin' >Molecular Weight</td><td align='left' valign='middle' style='border-top:solid thin' >430–550</td></tr><tr  ><td align='left' valign='middle' >Octanol/water partition coefficient (clog <span class='html-italic'>P</span>)</td><td align='left' valign='middle' >1–4</td></tr><tr  ><td align='left' valign='middle' >Aqueous solubility (clog <span class='html-italic'>S</span>)</td><td align='left' valign='middle' >(−3.3)–(−5.3)</td></tr><tr  ><td align='left' valign='middle' >Polar surface area (PSA, Å<sup>2</sup>)</td><td align='left' valign='middle' >90–160</td></tr><tr  ><td align='left' valign='middle' >Volume (Vol, Å<sup>3</sup>)</td><td align='left' valign='middle' >350–470</td></tr><tr  ><td align='left' valign='middle' style='border-bottom:solid thin' >Percent of oral absorption (%ABS)</td><td align='left' valign='middle' style='border-bottom:solid thin' >55–76</td></tr></tbody>
  </table>
  
</div></section></section><section id='sec3-molecules-21-00185' type=''><h2 data-nested='1'>  3. Computational Details</h2><div class='html-p'>Density functional theory (DFT) [<a href="#B50-molecules-21-00185" class="html-bibr">50</a>] calculations of edoxaban, eribaxaban, fidexaban, darexaban (YM150), letaxaban (TAK-442), tanogitran and SAR107375, (<a href="#molecules-21-00185-f001" class="html-fig">Figure 1</a>) were carried out with the Gaussian 09 computer code [<a href="#B51-molecules-21-00185" class="html-bibr">51</a>] employing the Becke3LYP [<a href="#B52-molecules-21-00185" class="html-bibr">52</a>,<a href="#B53-molecules-21-00185" class="html-bibr">53</a>,<a href="#B54-molecules-21-00185" class="html-bibr">54</a>], Grimme’s B97D [<a href="#B16-molecules-21-00185" class="html-bibr">16</a>] functionals and using 6-31++G(d,p) basis set [<a href="#B55-molecules-21-00185" class="html-bibr">55</a>]. The geometry optimization calculations of these drugs were also investigated in aqueous solution. The hydration free energy was computed using the polarizable continuum method within conductor-like polarizable continuum model (CPCM) [<a href="#B56-molecules-21-00185" class="html-bibr">56</a>]. Lipophilicity and water solubility calculations were carried out using web-based VCCLAB [<a href="#B36-molecules-21-00185" class="html-bibr">36</a>]. Calculations of macroscopic p<span class='html-italic'>K</span>a were carried out by means of the program SPARC [<a href="#B33-molecules-21-00185" class="html-bibr">33</a>] developed by Carreira <span class='html-italic'>et al.</span> [<a href="#B32-molecules-21-00185" class="html-bibr">32</a>]. For calculations of molecular volume and polar surface area, the fragment-based method of Ertl and coworkers [<a href="#B41-molecules-21-00185" class="html-bibr">41</a>] was used.</div></section><section id='sec4-molecules-21-00185' type='conclusions'><h2 data-nested='1'>  4. Conclusions</h2><div class='html-p'>In conclusion, the data presented in this theoretical study were able to determine the stable conformations, solvent effect, acidity, lipophilicity, solubility, absorption, and polar surface area of seven direct fXa inhibitors and two dual fXa and thrombin inhibitors for which a relatively small amount of experimental physicochemical data exist, considering their pharmacological importance. Using theoretical methods, the following conclusions can be drawn.
	  <dl class='html-roman-lower'><dt>i)</dt><dd><div class='html-p'>The fully optimized most stable conformers of these drugs possess a characteristic <span class='html-small-caps'>l</span>-shaped structure. Examination of the spatial models of the B3LYP and B97D optimized structures indicated that the equilibrium geometries computed using the B3LYP and B97D functionals are in some cases different.</div></dd><dt>ii)</dt><dd><div class='html-p'>Water had a remarkable effect on the geometry of the studied anticoagulants. The anticoagulant drugs exhibit considerable stability in this solvent, as expected.</div></dd><dt>iii)</dt><dd><div class='html-p'>Eribaxaban, and letaxaban are present in neutral undissociated form at pH 7.4. Fidexaban and tanogitran exist as zwitterionic structures.</div></dd><dt>iv)</dt><dd><div class='html-p'>A trend in the compound lipophilicity was also observed. It is lowest for the dual inhibitors tanogitran and SAR107375 and increase for the clinically approved fXa inhibitor edoxaban.</div></dd><dt>v)</dt><dd><div class='html-p'>The studied anticoagulants were only slightly soluble in water, but their computed solubility between 7 and 200 mg/L is sufficient for fast absorption.</div></dd><dt>vi)</dt><dd><div class='html-p'>The dual inhibitor SAR107375 represents an improvement in structural, physicochemical and pharmacokinetic characteristics over tanogitran. At blood p<span class='html-italic'>H</span>, SAR107375 predominantly exists in neutral form. In contrast to tanogitran, it is better absorbed and more lipophilic and active after oral application.</div></dd></dl></div></section>
  </div>
  <div class="html-back">
    <section><section id='app1-molecules-21-00185' type=''><h2 data-nested='1'>  Supplementary Materials</h2><div class='html-p'>The following are available online at: <a href='http://www.mdpi.com/1420-3049/21/2/185/s1' target='_blank'>http://www.mdpi.com/1420-3049/21/2/185/s1</a>. Figure S1: The geometries of the drugs studied. Molecule figures were generated using Mercury software., Table S1: Cartesian coordinates (Å) of the anticoagulants investigated, optimized at the B3LYP/6-31++G(d,p) level of the density functional theory.</div></section></section><section id='html-ack' class='html-ack'><h2 >Acknowledgments</h2><div class='html-p'>This work was supported by Medical Research Grant sponsored by Pfizer Slovakia (M.R. and A.R.).</div></section><section id='html-notes' class='html-notes'><h2 >Author Contributions</h2><div class='html-p'>M.R. carried out the computational study and wrote this paper, A.R. and R.B. revised this paper. All authors have read and approved the final manuscript.</div></section><section id='html-notes' class='html-notes'><h2 >Conflicts of Interest</h2><div class='html-p'>The authors declare no conflict of interest.</div></section><section id='html-references_list'><h2>References</h2><ol class='html-xx'><li id='B1-molecules-21-00185' class='html-x' data-content='1.'>Vermeer, C.; Schurgers, L.J. A comprehensive review of vitamin K and vitamin K antagonists. <span class='html-italic'>Hematol. Oncol. Clin. N. Am.</span> <b>2000</b>, <span class='html-italic'>14</span>, 339–353. [<a href="http://scholar.google.com/scholar_lookup?title=A comprehensive review of vitamin K and vitamin K antagonists&author=Vermeer,+C.&author=Schurgers,+L.J.&publication_year=2000&journal=Hematol.+Oncol.+Clin.+N.+Am.&volume=14&pages=339–353" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B2-molecules-21-00185' class='html-x' data-content='2.'>Becattini, C.; Vedovati, M.C.; Agnelli, G. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature. <span class='html-italic'>Thromb. Res.</span> <b>2012</b>, <span class='html-italic'>129</span>, 392–400. [<a href="http://scholar.google.com/scholar_lookup?title=Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature&author=Becattini,+C.&author=Vedovati,+M.C.&author=Agnelli,+G.&publication_year=2012&journal=Thromb.+Res.&volume=129&pages=392–400&doi=10.1016/j.thromres.2011.12.014&pmid=22264937" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1016/j.thromres.2011.12.014" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/22264937" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B3-molecules-21-00185' class='html-x' data-content='3.'>Scaglione, F. New oral anticoagulants: Comparative pharmacology with vitamin K antagonists. <span class='html-italic'>Clin. Pharmacokinet.</span> <b>2013</b>, <span class='html-italic'>52</span>, 69–82. [<a href="http://scholar.google.com/scholar_lookup?title=New oral anticoagulants: Comparative pharmacology with vitamin K antagonists&author=Scaglione,+F.&publication_year=2013&journal=Clin.+Pharmacokinet.&volume=52&pages=69–82&doi=10.1007/s40262-012-0030-9&pmid=23292752" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1007/s40262-012-0030-9" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/23292752" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B4-molecules-21-00185' class='html-x' data-content='4.'>Pinto, D.J.P.; Smallheer, J.M.; Cheney, D.L.; Knabb, R.M.; Wexler, R.R. Factor Xa inhibitors: Next-generation antithrombotic agents. <span class='html-italic'>J. Med. Chem.</span> <b>2010</b>, <span class='html-italic'>53</span>, 6243–6274. [<a href="http://scholar.google.com/scholar_lookup?title=Factor Xa inhibitors: Next-generation antithrombotic agents&author=Pinto,+D.J.P.&author=Smallheer,+J.M.&author=Cheney,+D.L.&author=Knabb,+R.M.&author=Wexler,+R.R.&publication_year=2010&journal=J.+Med.+Chem.&volume=53&pages=6243–6274&pmid=20503967" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/20503967" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B5-molecules-21-00185' class='html-x' data-content='5.'>Levy, J.H.; Spyropoulos, A.C.; Samama, C.M.; Douketis, J. Direct oral anticoagulants: New drugs and new concepts. <span class='html-italic'>JACC Cardiovasc. Interv.</span> <b>2014</b>, <span class='html-italic'>7</span>, 1333–1351. [<a href="http://scholar.google.com/scholar_lookup?title=Direct oral anticoagulants: New drugs and new concepts&author=Levy,+J.H.&author=Spyropoulos,+A.C.&author=Samama,+C.M.&author=Douketis,+J.&publication_year=2014&journal=JACC+Cardiovasc.+Interv.&volume=7&pages=1333–1351&pmid=25523529" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/25523529" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B6-molecules-21-00185' class='html-x' data-content='6.'>Schwienhorst, A. Direct thrombin inhibitors—A survey of recent developments. <span class='html-italic'>Cell. Mol. Life Sci.</span> <b>2006</b>, <span class='html-italic'>63</span>, 2773–2791. [<a href="http://scholar.google.com/scholar_lookup?title=Direct thrombin inhibitors—A survey of recent developments&author=Schwienhorst,+A.&publication_year=2006&journal=Cell.+Mol.+Life+Sci.&volume=63&pages=2773–2791&pmid=17103113" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/17103113" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B7-molecules-21-00185' class='html-x' data-content='7.'>Graefe-Mody, E.U.; Schühly, U.; Rathgen, K.; Stähle, H.; Leitner, M.J.; Jilma, B. Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. <span class='html-italic'>J. Thromb. Haemost.</span> <b>2006</b>, <span class='html-italic'>4</span>, 1502–1509. [<a href="http://scholar.google.com/scholar_lookup?title=Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa&author=Graefe-Mody,+E.U.&author=Schühly,+U.&author=Rathgen,+K.&author=Stähle,+H.&author=Leitner,+M.J.&author=Jilma,+B.&publication_year=2006&journal=J.+Thromb.+Haemost.&volume=4&pages=1502–1509&doi=10.1111/j.1538-7836.2006.02020.x&pmid=16839346" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1111/j.1538-7836.2006.02020.x" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16839346" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B8-molecules-21-00185' class='html-x' data-content='8.'>He, L.W.; Dai, W.Ch.; Li, N.G. Development of orally active thrombin inhibitors for the treatment of thrombotic disorder diseases. <span class='html-italic'>Molecules</span> <b>2015</b>, <span class='html-italic'>20</span>, 11046–11062. [<a href="http://scholar.google.com/scholar_lookup?title=Development of orally active thrombin inhibitors for the treatment of thrombotic disorder diseases&author=He,+L.W.&author=Dai,+W.Ch.&author=Li,+N.G.&publication_year=2015&journal=Molecules&volume=20&pages=11046–11062&doi=10.3390/molecules200611046&pmid=26083038" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.3390/molecules200611046" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/26083038" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B9-molecules-21-00185' class='html-x' data-content='9.'>Giardino, E.C.; Haertlein, B.J.; de Garavilla, L.; Costanzo, M.J.; Damiano, B.P.; Andrade-Gordon, P.; Maryanoff, B.E. Cooperative antithrombotic effect from the simultaneous inhibition of thrombin and factor Xa. <span class='html-italic'>Blood Coagul. Fibrinol.</span> <b>2010</b>, <span class='html-italic'>21</span>, 128–134. [<a href="http://scholar.google.com/scholar_lookup?title=Cooperative antithrombotic effect from the simultaneous inhibition of thrombin and factor Xa&author=Giardino,+E.C.&author=Haertlein,+B.J.&author=de+Garavilla,+L.&author=Costanzo,+M.J.&author=Damiano,+B.P.&author=Andrade-Gordon,+P.&author=Maryanoff,+B.E.&publication_year=2010&journal=Blood+Coagul.+Fibrinol.&volume=21&pages=128–134" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B10-molecules-21-00185' class='html-xx' data-content='10.'>Nar, H. The role of structural information in the discovery of direct thrombin and factor Xa inhibitors. <span class='html-italic'>Trends Pharmacol. Sci.</span> <b>2012</b>, <span class='html-italic'>33</span>, 279–288. [<a href="http://scholar.google.com/scholar_lookup?title=The role of structural information in the discovery of direct thrombin and factor Xa inhibitors&author=Nar,+H.&publication_year=2012&journal=Trends+Pharmacol.+Sci.&volume=33&pages=279–288&pmid=22503439" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/22503439" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B11-molecules-21-00185' class='html-xx' data-content='11.'>Remko, M. Molecular structure, lipophilicity, solubility, absorption, and polar surface area of novel anticoagulant agents. <span class='html-italic'>J. Mol. Struct.</span> <b>2009</b>, <span class='html-italic'>916</span>, 76–85. [<a href="http://scholar.google.com/scholar_lookup?title=Molecular structure, lipophilicity, solubility, absorption, and polar surface area of novel anticoagulant agents&author=Remko,+M.&publication_year=2009&journal=J.+Mol.+Struct.&volume=916&pages=76–85" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B12-molecules-21-00185' class='html-xx' data-content='12.'>Remko, M.; Broer, R.; Remková, A. A comparative study of the molecular structure, lipophilicity, solubility, acidity, absorption and polar surface area of coumarinic anticoagulants and direct thrombin inhibitors. <span class='html-italic'>RSC Adv.</span> <b>2014</b>, <span class='html-italic'>4</span>, 8072–8084. [<a href="http://scholar.google.com/scholar_lookup?title=A comparative study of the molecular structure, lipophilicity, solubility, acidity, absorption and polar surface area of coumarinic anticoagulants and direct thrombin inhibitors&author=Remko,+M.&author=Broer,+R.&author=Remková,+A.&publication_year=2014&journal=RSC+Adv.&volume=4&pages=8072–8084" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B13-molecules-21-00185' class='html-xx' data-content='13.'>Sebastiani, D.; Röthlisberger, U.; Cavalli, A.; Folkers, G.; Recanatini, M.; Scapozza, L.; Rovira, C.; Raber, J.; Llano, J.; Eriksson, L.A.; <span class='html-italic'>et al</span>. <span class='html-italic'>Quantum Medicinal Chemistry</span>; Carloni, P., Alber, F., Eds.;  Wiley-VCH: Weinheim, Germany, 2003. [<a href="http://scholar.google.com/scholar_lookup?title=Quantum+Medicinal+Chemistry&author=Sebastiani,+D.&author=Röthlisberger,+U.&author=Cavalli,+A.&author=Folkers,+G.&author=Recanatini,+M.&author=Scapozza,+L.&author=Rovira,+C.&author=Raber,+J.&author=Llano,+J.&author=Eriksson,+L.A.&publication_year=2003" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B14-molecules-21-00185' class='html-xx' data-content='14.'>Ooms, F. Molecular modeling and computer aided drug design. Examples of their applications in medicinal chemistry. <span class='html-italic'>Curr. Med. Chem.</span> <b>2000</b>, <span class='html-italic'>7</span>, 141–158. [<a href="http://scholar.google.com/scholar_lookup?title=Molecular modeling and computer aided drug design. Examples of their applications in medicinal chemistry&author=Ooms,+F.&publication_year=2000&journal=Curr.+Med.+Chem.&volume=7&pages=141–158&doi=10.2174/0929867003375317&pmid=10637360" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.2174/0929867003375317" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/10637360" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B15-molecules-21-00185' class='html-xx' data-content='15.'>Sliwoski, G.; Kothiwale, S.; Meiler, J.; Lowe, E.W., Jr. Computational methods in drug discovery. <span class='html-italic'>Pharmacol. Rev.</span> <b>2014</b>, <span class='html-italic'>66</span>, 334–395. [<a href="http://scholar.google.com/scholar_lookup?title=Computational methods in drug discovery&author=Sliwoski,+G.&author=Kothiwale,+S.&author=Meiler,+J.&author=Lowe,+E.W.,+Jr.&publication_year=2014&journal=Pharmacol.+Rev.&volume=66&pages=334–395&pmid=24381236" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/24381236" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B16-molecules-21-00185' class='html-xx' data-content='16.'>Grimme, S. Semiempirical GGA-type density functional constructed with a long-range dispersion correction. <span class='html-italic'>J. Comput. Chem.</span> <b>2006</b>, <span class='html-italic'>27</span>, 1787–1799. [<a href="http://scholar.google.com/scholar_lookup?title=Semiempirical GGA-type density functional constructed with a long-range dispersion correction&author=Grimme,+S.&publication_year=2006&journal=J.+Comput.+Chem.&volume=27&pages=1787–1799&pmid=16955487" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16955487" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B17-molecules-21-00185' class='html-xx' data-content='17.'>Minor, Ch.; Tellor, K.B.; Armbruster, A.L. Edoxaban, a novel oral factor Xa inhibitor. <span class='html-italic'>Ann. Pharmacother.</span> <b>2015</b>, <span class='html-italic'>49</span>, 843–850. [<a href="http://scholar.google.com/scholar_lookup?title=Edoxaban, a novel oral factor Xa inhibitor&author=Minor,+Ch.&author=Tellor,+K.B.&author=Armbruster,+A.L.&publication_year=2015&journal=Ann.+Pharmacother.&volume=49&pages=843–850&doi=10.1177/1060028015579426&pmid=25855704" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1177/1060028015579426" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/25855704" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B18-molecules-21-00185' class='html-xx' data-content='18.'>Kahn, R.; Fourme, R.; André, D.; Renaud, M. Crystal structure of cyclohexane I and II. <span class='html-italic'>Acta Crystallogr. B</span> <b>1973</b>, <span class='html-italic'>29</span>, 131–138. [<a href="http://scholar.google.com/scholar_lookup?title=Crystal structure of cyclohexane I and II&author=Kahn,+R.&author=Fourme,+R.&author=André,+D.&author=Renaud,+M.&publication_year=1973&journal=Acta+Crystallogr.+B&volume=29&pages=131–138&doi=10.1107/S0567740873002074" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1107/S0567740873002074" class='cross-ref' target='_blank'>CrossRef</a>]</li><li id='B19-molecules-21-00185' class='html-xx' data-content='19.'>Kohrt, J.T.; Bigge, C.F.; Bryant, J.W.; Casimiro-Garcia, A.; Chi, L.; Cody, WL.; Dahring, T.; Dudley, D.A.; Filipski, K.J.; Haarer, S.; <span class='html-italic'>et al</span>. The Discovery of (2<span class='html-italic'>R</span>,4<span class='html-italic'>R</span>)-<span class='html-italic'>N</span>-(4-chlorophenyl)-<span class='html-italic'>N</span>-(2-fluoro-4-(2-oxopyridin-1(2<span class='html-italic'>H</span>)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor. <span class='html-italic'>Chem. Biol. Drug Des.</span> <b>2007</b>, <span class='html-italic'>70</span>, 100–112. [<a href="http://scholar.google.com/scholar_lookup?title=The Discovery of (2R,4R)-N-(4-chlorophenyl)-N-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor&author=Kohrt,+J.T.&author=Bigge,+C.F.&author=Bryant,+J.W.&author=Casimiro-Garcia,+A.&author=Chi,+L.&author=Cody,+WL.&author=Dahring,+T.&author=Dudley,+D.A.&author=Filipski,+K.J.&author=Haarer,+S.&publication_year=2007&journal=Chem.+Biol.+Drug+Des.&volume=70&pages=100–112&pmid=17683371" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/17683371" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B20-molecules-21-00185' class='html-xx' data-content='20.'>Ahrens, I.; Peter, K.; Lip, G.Y.; Bode, C. Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation. <span class='html-italic'>Discov. Med.</span> <b>2012</b>, <span class='html-italic'>13</span>, 445–450. [<a href="http://scholar.google.com/scholar_lookup?title=Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation&author=Ahrens,+I.&author=Peter,+K.&author=Lip,+G.Y.&author=Bode,+C.&publication_year=2012&journal=Discov.+Med.&volume=13&pages=445–450&pmid=22742650" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/22742650" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B21-molecules-21-00185' class='html-xx' data-content='21.'>Phillips, G.B.; Buckman, B.O.; Davey, D.D.; Eagen, K.A.; Guilford, W.J.; Hinchman, J.; Ho, E.; Koovakkat, S.; Liang, A.; Light, D.R.; <span class='html-italic'>et al</span>. Discovery of <span class='html-italic'>N</span>-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3,5-difluoro-6-[3-(4,5-dihydro-1-methyl-1<span class='html-italic'>H</span>-imidazol-2-yl)phenoxy]pyridin-4-yl]-<span class='html-italic'>N</span>-methylglycine (ZK-807834): A potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa. <span class='html-italic'>J. Med. Chem.</span> <b>1998</b>, <span class='html-italic'>41</span>, 3557–3562. [<a href="http://scholar.google.com/scholar_lookup?title=Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3,5-difluoro-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylglycine (ZK-807834): A potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa&author=Phillips,+G.B.&author=Buckman,+B.O.&author=Davey,+D.D.&author=Eagen,+K.A.&author=Guilford,+W.J.&author=Hinchman,+J.&author=Ho,+E.&author=Koovakkat,+S.&author=Liang,+A.&author=Light,+D.R.&publication_year=1998&journal=J.+Med.+Chem.&volume=41&pages=3557–3562&pmid=9733480" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/9733480" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B22-molecules-21-00185' class='html-xx' data-content='22.'>Adler, M.; Davey, D.D.; Phillips, G.B.; Kim, S.H.; Jancarik, J.; Rumennik, G.; Light, D.R.; Whitlow, M. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. <span class='html-italic'>Biochemistry</span> <b>2000</b>, <span class='html-italic'>39</span>, 12534–12542. [<a href="http://scholar.google.com/scholar_lookup?title=Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa&author=Adler,+M.&author=Davey,+D.D.&author=Phillips,+G.B.&author=Kim,+S.H.&author=Jancarik,+J.&author=Rumennik,+G.&author=Light,+D.R.&author=Whitlow,+M.&publication_year=2000&journal=Biochemistry&volume=39&pages=12534–12542&pmid=11027132" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/11027132" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B23-molecules-21-00185' class='html-xx' data-content='23.'>Hirayama, F.; Koshio, H.; Ishihara, T.; Hachiya, S.; Sugasawa, K.; Koga, Y.; Seki, N.; Shiraki, R.; Shigenaga, T.; Iwatsuki, Y.; <span class='html-italic'>et al</span>. Discovery of <span class='html-italic'>N</span>-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide (Darexaban, YM150) as a potent and orally available factor Xa inhibitor. <span class='html-italic'>J. Med. Chem.</span> <b>2011</b>, <span class='html-italic'>54</span>, 8051–8065. [<a href="http://scholar.google.com/scholar_lookup?title=Discovery of N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide (Darexaban, YM150) as a potent and orally available factor Xa inhibitor&author=Hirayama,+F.&author=Koshio,+H.&author=Ishihara,+T.&author=Hachiya,+S.&author=Sugasawa,+K.&author=Koga,+Y.&author=Seki,+N.&author=Shiraki,+R.&author=Shigenaga,+T.&author=Iwatsuki,+Y.&publication_year=2011&journal=J.+Med.+Chem.&volume=54&pages=8051–8065&pmid=21995444" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/21995444" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B24-molecules-21-00185' class='html-xx' data-content='24.'>Fujimoto, T.; Imaeda, Y.; Konishi, N.; Hiroe, K.; Kawamura, M.; Textor, G.P.; Aertgeerts, K.; Kubo, K. Discovery of a tetrahydropyrimidin-2(1<span class='html-italic'>H</span>)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor. <span class='html-italic'>J. Med. Chem.</span> <b>2010</b>, <span class='html-italic'>53</span>, 3517–3531. [<a href="http://scholar.google.com/scholar_lookup?title=Discovery of a tetrahydropyrimidin-2(1H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor&author=Fujimoto,+T.&author=Imaeda,+Y.&author=Konishi,+N.&author=Hiroe,+K.&author=Kawamura,+M.&author=Textor,+G.P.&author=Aertgeerts,+K.&author=Kubo,+K.&publication_year=2010&journal=J.+Med.+Chem.&volume=53&pages=3517–3531&pmid=20355714" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/20355714" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B25-molecules-21-00185' class='html-xx' data-content='25.'>Remko, M.; Herich, P.; Gregáň, F.; Kožíšek, J. Structure, acidity and basicity of a benzene disulfonamide inhibitor of carbonic anhydrase. <span class='html-italic'>J. Mol. Struct.</span> <b>2014</b>, <span class='html-italic'>1059</span>, 124–131. [<a href="http://scholar.google.com/scholar_lookup?title=Structure, acidity and basicity of a benzene disulfonamide inhibitor of carbonic anhydrase&author=Remko,+M.&author=Herich,+P.&author=Gregáň,+F.&author=Kožíšek,+J.&publication_year=2014&journal=J.+Mol.+Struct.&volume=1059&pages=124–131&doi=10.1016/j.molstruc.2013.11.047" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1016/j.molstruc.2013.11.047" class='cross-ref' target='_blank'>CrossRef</a>]</li><li id='B26-molecules-21-00185' class='html-xx' data-content='26.'>Remko, M.; Kožíšek, J.; Semanová, J.; Gregáň, F. Synthesis, crystal and molecular structure of two biologically active aromatic sulfonamides and their hydrochloride salts. <span class='html-italic'>J. Mol. Struct.</span> <b>2010</b>, <span class='html-italic'>973</span>, 18–26. [<a href="http://scholar.google.com/scholar_lookup?title=Synthesis, crystal and molecular structure of two biologically active aromatic sulfonamides and their hydrochloride salts&author=Remko,+M.&author=Kožíšek,+J.&author=Semanová,+J.&author=Gregáň,+F.&publication_year=2010&journal=J.+Mol.+Struct.&volume=973&pages=18–26&doi=10.1016/j.molstruc.2010.03.013" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1016/j.molstruc.2010.03.013" class='cross-ref' target='_blank'>CrossRef</a>]</li><li id='B27-molecules-21-00185' class='html-xx' data-content='27.'>Leitner, J.M.; Jilma, B.; Mayr, F.B.; Cardona, F.; Spiel, A.O.; Firbas, C.; Rathgen, K.; Stähl, H.; Schühly, U.; Graefe-Mody, E.U. Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation. <span class='html-italic'>Clin. Pharmacol. Ther.</span> <b>2007</b>, <span class='html-italic'>81</span>, 858–866. [<a href="http://scholar.google.com/scholar_lookup?title=Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation&author=Leitner,+J.M.&author=Jilma,+B.&author=Mayr,+F.B.&author=Cardona,+F.&author=Spiel,+A.O.&author=Firbas,+C.&author=Rathgen,+K.&author=Stähl,+H.&author=Schühly,+U.&author=Graefe-Mody,+E.U.&publication_year=2007&journal=Clin.+Pharmacol.+Ther.&volume=81&pages=858–866&doi=10.1038/sj.clpt.6100153&pmid=17410124" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1038/sj.clpt.6100153" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/17410124" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B28-molecules-21-00185' class='html-xx' data-content='28.'>Meneyrol, J.; Follmann, M.; Lassalle, G.; Wehner, V.; Barre, G.; Rousseaux, T.; Altenburger, J.-M.; Petit, F.; Bocskei, Z.; Schreuder, H.; <span class='html-italic'>et al</span>. 5-Chlorothiophene-2-carboxylic acid [(<span class='html-italic'>S</span>)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor. <span class='html-italic'>J. Med. Chem.</span> <b>2013</b>, <span class='html-italic'>56</span>, 9441–9456. [<a href="http://scholar.google.com/scholar_lookup?title=5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor&author=Meneyrol,+J.&author=Follmann,+M.&author=Lassalle,+G.&author=Wehner,+V.&author=Barre,+G.&author=Rousseaux,+T.&author=Altenburger,+J.-M.&author=Petit,+F.&author=Bocskei,+Z.&author=Schreuder,+H.&publication_year=2013&journal=J.+Med.+Chem.&volume=56&pages=9441–9456&pmid=24175584" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/24175584" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B29-molecules-21-00185' class='html-xx' data-content='29.'>Bondi, A. Van der Waals volumes and radii. <span class='html-italic'>J. Phys. Chem.</span> <b>1964</b>, <span class='html-italic'>68</span>, 441–451. [<a href="http://scholar.google.com/scholar_lookup?title=Van der Waals volumes and radii&author=Bondi,+A.&publication_year=1964&journal=J.+Phys.+Chem.&volume=68&pages=441–451&doi=10.1021/j100785a001" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1021/j100785a001" class='cross-ref' target='_blank'>CrossRef</a>]</li><li id='B30-molecules-21-00185' class='html-xx' data-content='30.'>Remko, M. Molecular structure, p<span class='html-italic'>K</span>a, lipophilicity, solubility and absorption of biologically active aromatic and heterocyclic sulfonamides. <span class='html-italic'>J. Mol. Struct.</span> <b>2010</b>, <span class='html-italic'>944</span>, 34–42. [<a href="http://scholar.google.com/scholar_lookup?title=Molecular structure, pKa, lipophilicity, solubility and absorption of biologically active aromatic and heterocyclic sulfonamides&author=Remko,+M.&publication_year=2010&journal=J.+Mol.+Struct.&volume=944&pages=34–42&doi=10.1016/j.theochem.2009.12.017" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1016/j.theochem.2009.12.017" class='cross-ref' target='_blank'>CrossRef</a>]</li><li id='B31-molecules-21-00185' class='html-xx' data-content='31.'>Zhou, F.; Liu, R.; Li, P.; Zhang, H. On the properties of S···O and S···π noncovalent interactions: The analysis of geometry, interaction energy and electron density. <span class='html-italic'>New J. Chem.</span> <b>2015</b>, <span class='html-italic'>39</span>, 1611–1618. [<a href="http://scholar.google.com/scholar_lookup?title=On the properties of S···O and S···π noncovalent interactions: The analysis of geometry, interaction energy and electron density&author=Zhou,+F.&author=Liu,+R.&author=Li,+P.&author=Zhang,+H.&publication_year=2015&journal=New+J.+Chem.&volume=39&pages=1611–1618" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B32-molecules-21-00185' class='html-xx' data-content='32.'>Hilal, S.; Karickhoff, S.W.; Carreira, L.A. A Rigorous test for SPARC’s chemical reactivity models: Estimation of more than 4300 ionization p<span class='html-italic'>K</span>as. <span class='html-italic'>Quant. Struc. Act. Real.</span> <b>1995</b>, <span class='html-italic'>14</span>, 348–355. [<a href="http://scholar.google.com/scholar_lookup?title=A Rigorous test for SPARC’s chemical reactivity models: Estimation of more than 4300 ionization pKas&author=Hilal,+S.&author=Karickhoff,+S.W.&author=Carreira,+L.A.&publication_year=1995&journal=Quant.+Struc.+Act.+Real.&volume=14&pages=348–355" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B33-molecules-21-00185' class='html-xx' data-content='33.'>SPARC. Available online:  <a href='http://archemcalc.com/sparc/' target='_blank' >http://archemcalc.com/sparc/</a> (accessed on 15 September 2015).</li><li id='B34-molecules-21-00185' class='html-xx' data-content='34.'>Malkia, A.; Murtomaki, L.; Urtti, A.; Kontturi, K. Drug permeation in biomembranes: <span class='html-italic'>In vitro</span> and <span class='html-italic'>in silico</span> prediction and influence of physicochemical properties. <span class='html-italic'>Eur. J. Pharm. Sci.</span> <b>2004</b>, <span class='html-italic'>23</span>, 13–47. [<a href="http://scholar.google.com/scholar_lookup?title=Drug permeation in biomembranes: In vitro and in silico prediction and influence of physicochemical properties&author=Malkia,+A.&author=Murtomaki,+L.&author=Urtti,+A.&author=Kontturi,+K.&publication_year=2004&journal=Eur.+J.+Pharm.+Sci.&volume=23&pages=13–47&pmid=15324921" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/15324921" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B35-molecules-21-00185' class='html-xx' data-content='35.'>Drug Bank. Available online:  <a href='http://www.drugbank.ca/drugs/DB09075' target='_blank' >http://www.drugbank.ca/drugs/DB09075</a> (accessed on 10 January 2016).</li><li id='B36-molecules-21-00185' class='html-xx' data-content='36.'>Tetko, I.V.; Gasteiger, J.; Todeschini, R.; Mauri, A.; Livingstone, D.; Ertl, P.; Palyulin, V.A.; Radchenko, E.V.; Zefirov, N.S.; Makarenko, A.S.; <span class='html-italic'>et al</span>. Virtual computational chemistry laboratory—Design and description. <span class='html-italic'>J. Comput. Aided Mol. Des.</span> <b>2005</b>, <span class='html-italic'>19</span>, 453–463. [<a href="http://scholar.google.com/scholar_lookup?title=Virtual computational chemistry laboratory—Design and description&author=Tetko,+I.V.&author=Gasteiger,+J.&author=Todeschini,+R.&author=Mauri,+A.&author=Livingstone,+D.&author=Ertl,+P.&author=Palyulin,+V.A.&author=Radchenko,+E.V.&author=Zefirov,+N.S.&author=Makarenko,+A.S.&publication_year=2005&journal=J.+Comput.+Aided+Mol.+Des.&volume=19&pages=453–463&pmid=16231203" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16231203" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B37-molecules-21-00185' class='html-xx' data-content='37.'>Xing, L.; Glen, R.C. Novel Methods for the Prediction of logP, p<span class='html-italic'>K</span>a, and logD. <span class='html-italic'>J. Chem. Inf. Comput. Sci.</span> <b>2002</b>, <span class='html-italic'>42</span>, 796–805. [<a href="http://scholar.google.com/scholar_lookup?title=Novel Methods for the Prediction of logP, pKa, and logD&author=Xing,+L.&author=Glen,+R.C.&publication_year=2002&journal=J.+Chem.+Inf.+Comput.+Sci.&volume=42&pages=796–805&pmid=12132880" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/12132880" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B38-molecules-21-00185' class='html-xx' data-content='38.'>Veber, D.F.; Johnson, R.S.; Cheng, H.Y.; Smith, B.R.; Ward, K.W.; Kapple, K.D. Molecular properties that influence the oral bioavailability of drug candidates. <span class='html-italic'>J. Med. Chem.</span> <b>2002</b>, <span class='html-italic'>45</span>, 2615–2623. [<a href="http://scholar.google.com/scholar_lookup?title=Molecular properties that influence the oral bioavailability of drug candidates&author=Veber,+D.F.&author=Johnson,+R.S.&author=Cheng,+H.Y.&author=Smith,+B.R.&author=Ward,+K.W.&author=Kapple,+K.D.&publication_year=2002&journal=J.+Med.+Chem.&volume=45&pages=2615–2623&pmid=12036371" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/12036371" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B39-molecules-21-00185' class='html-xx' data-content='39.'>Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. <span class='html-italic'>Adv. Drug Deliv. Rev.</span> <b>1997</b>, <span class='html-italic'>23</span>, 3–25. [<a href="http://scholar.google.com/scholar_lookup?title=Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings&author=Lipinski,+C.A.&author=Lombardo,+F.&author=Dominy,+B.W.&author=Feeney,+P.J.&publication_year=1997&journal=Adv.+Drug+Deliv.+Rev.&volume=23&pages=3–25" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B40-molecules-21-00185' class='html-xx' data-content='40.'>Zhao, Y.H.; Abraham, M.H.; Lee, J.; Hersey, A.; Luscombe, C.N.; Beck, G.; Sherborne, B. Cooper, Rate-limited steps of human oral absorption and QSAR studies. <span class='html-italic'>Pharm. Res.</span> <b>2002</b>, <span class='html-italic'>19</span>, 1446–1457. [<a href="http://scholar.google.com/scholar_lookup?title=Cooper, Rate-limited steps of human oral absorption and QSAR studies&author=Zhao,+Y.H.&author=Abraham,+M.H.&author=Lee,+J.&author=Hersey,+A.&author=Luscombe,+C.N.&author=Beck,+G.&author=Sherborne,+B.&publication_year=2002&journal=Pharm.+Res.&volume=19&pages=1446–1457&pmid=12425461" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/12425461" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B41-molecules-21-00185' class='html-xx' data-content='41.'>Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. <span class='html-italic'>J. Med. Chem.</span> <b>2000</b>, <span class='html-italic'>43</span>, 3714–3717. [<a href="http://scholar.google.com/scholar_lookup?title=Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties&author=Ertl,+P.&author=Rohde,+B.&author=Selzer,+P.&publication_year=2000&journal=J.+Med.+Chem.&volume=43&pages=3714–3717&pmid=11020286" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/11020286" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B42-molecules-21-00185' class='html-xx' data-content='42.'>Gómez-Outes, A.; Suárez-Gea, M.L.; Lecumberri, R.; Terleira-Fernández, A.I.; Vargas-Castrillón, E.; Rocha, E. Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. <span class='html-italic'>Vasc. Health Risk Manag.</span> <b>2013</b>, <span class='html-italic'>9</span>, 207–228. [<a href="http://scholar.google.com/scholar_lookup?title=Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients&author=Gómez-Outes,+A.&author=Suárez-Gea,+M.L.&author=Lecumberri,+R.&author=Terleira-Fernández,+A.I.&author=Vargas-Castrillón,+E.&author=Rocha,+E.&publication_year=2013&journal=Vasc.+Health+Risk+Manag.&volume=9&pages=207–228&doi=10.2147/VHRM.S35843&pmid=23674896" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.2147/VHRM.S35843" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/23674896" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B43-molecules-21-00185' class='html-xx' data-content='43.'>Liu, T.; Lin, Y.; Wen, X.; Jorrisen, R.N.; Gilson, M.K. <span class='html-italic'>BindingDB</span>: A web-accessible database of experimentally determined protein-ligand binding affinities. <span class='html-italic'>Nucleic Acids Res.</span> <b>2007</b>, <span class='html-italic'>35</span>, D198–D201. [<a href="http://scholar.google.com/scholar_lookup?title=BindingDB: A web-accessible database of experimentally determined protein-ligand binding affinities&author=Liu,+T.&author=Lin,+Y.&author=Wen,+X.&author=Jorrisen,+R.N.&author=Gilson,+M.K.&publication_year=2007&journal=Nucleic+Acids+Res.&volume=35&pages=D198–D201&doi=10.1093/nar/gkl999&pmid=17145705" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1093/nar/gkl999" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/17145705" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B44-molecules-21-00185' class='html-xx' data-content='44.'>Liu, Z.; Li, Y.; Han, L.; Li, J.; Liu, J.; Zhao, Z.; Nie, W.; Liu, Y.; Wang, R. PDB-wide collection of binding data: Current status of the PDBbind database. <span class='html-italic'>Bioinformatics</span> <b>2015</b>, <span class='html-italic'>31</span>, 405–412. [<a href="http://scholar.google.com/scholar_lookup?title=PDB-wide collection of binding data: Current status of the PDBbind database&author=Liu,+Z.&author=Li,+Y.&author=Han,+L.&author=Li,+J.&author=Liu,+J.&author=Zhao,+Z.&author=Nie,+W.&author=Liu,+Y.&author=Wang,+R.&publication_year=2015&journal=Bioinformatics&volume=31&pages=405–412&pmid=25301850" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/25301850" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B45-molecules-21-00185' class='html-xx' data-content='45.'>Toschi, V.; Lettino, M. Inhibitors of propagation of coagulation: Factors V and X. <span class='html-italic'>Br. J. Clin. Pharmacol.</span> <b>2011</b>, <span class='html-italic'>72</span>, 563–580. [<a href="http://scholar.google.com/scholar_lookup?title=Inhibitors of propagation of coagulation: Factors V and X&author=Toschi,+V.&author=Lettino,+M.&publication_year=2011&journal=Br.+J.+Clin.+Pharmacol.&volume=72&pages=563–580&pmid=21545479" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/21545479" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B46-molecules-21-00185' class='html-xx' data-content='46.'>Masotti, L.; Campanini, M. Pharmacology of new oral anticoagulants: Mechanism of action, pharmacokinetics, pharmacodynamics. <span class='html-italic'>Italian J. Med.</span> <b>2013</b>, <span class='html-italic'>7</span>, 1–7. [<a href="http://scholar.google.com/scholar_lookup?title=Pharmacology of new oral anticoagulants: Mechanism of action, pharmacokinetics, pharmacodynamics&author=Masotti,+L.&author=Campanini,+M.&publication_year=2013&journal=Italian+J.+Med.&volume=7&pages=1–7" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B47-molecules-21-00185' class='html-xx' data-content='47.'>Weitz, J.I.; Eikelboom, J.W.; Samama, M.M. New antithrombotic drugs, antithrombotic therapy and prevention of thrombosis: American college of chest physicians, evidence-based clinical practice guidelines. <span class='html-italic'>Chest</span> <b>2012</b>, <span class='html-italic'>141</span> (Suppl. S2), e120S–e151S. [<a href="http://scholar.google.com/scholar_lookup?title=New antithrombotic drugs, antithrombotic therapy and prevention of thrombosis: American college of chest physicians, evidence-based clinical practice guidelines&author=Weitz,+J.I.&author=Eikelboom,+J.W.&author=Samama,+M.M.&publication_year=2012&journal=Chest&volume=141&pages=e120S–e151S&pmid=22315258" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/22315258" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B48-molecules-21-00185' class='html-xx' data-content='48.'>Arnott, J.A.; Planey, S.L. The influence of lipophilicity in drug discovery and design. <span class='html-italic'>Expert Opin. Drug Discov.</span> <b>2012</b>, <span class='html-italic'>7</span>, 863–875. [<a href="http://scholar.google.com/scholar_lookup?title=The influence of lipophilicity in drug discovery and design&author=Arnott,+J.A.&author=Planey,+S.L.&publication_year=2012&journal=Expert+Opin.+Drug+Discov.&volume=7&pages=863–875&pmid=22992175" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/22992175" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B49-molecules-21-00185' class='html-xx' data-content='49.'>Kontogiorgis, C.A.; Hadjipavlou-Litina, D. Current trends in quantitative structure activity relationships on fxa inhibitors: Evaluation and comparative analysis. <span class='html-italic'>Med. Res. Rev.</span> <b>2004</b>, <span class='html-italic'>24</span>, 687–747. [<a href="http://scholar.google.com/scholar_lookup?title=Current trends in quantitative structure activity relationships on fxa inhibitors: Evaluation and comparative analysis&author=Kontogiorgis,+C.A.&author=Hadjipavlou-Litina,+D.&publication_year=2004&journal=Med.+Res.+Rev.&volume=24&pages=687–747&pmid=15250038" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/15250038" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B50-molecules-21-00185' class='html-xx' data-content='50.'>Bickelhaupt, F.M.; Baerends, E.J. Kohn-sham density functional theory: Predicting and understanding chemistry. In <span class='html-italic'>Reviews in Computational Chemistry</span>; Lipkowitz, K.B., Boyd, D.B., Eds.;  Wiley-VCH: New York, NY, USA, 2000; Volume 15, pp. 1–86. [<a href="http://scholar.google.com/scholar_lookup?title=Kohn-sham density functional theory: Predicting and understanding chemistry&author=Bickelhaupt,+F.M.&author=Baerends,+E.J.&publication_year=2000&pages=1–86" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B51-molecules-21-00185' class='html-xx' data-content='51.'><span class='html-italic'>Gaussian 09</span>; version 9.0; Gaussian, Inc.: Wallingford, CT, USA, 2011.</li><li id='B52-molecules-21-00185' class='html-xx' data-content='52.'>Becke, D. Density-functional thermochemistry. III. The role of exact exchange. <span class='html-italic'>J. Chem. Phys.</span> <b>1993</b>, <span class='html-italic'>98</span>, 5648–5652. [<a href="http://scholar.google.com/scholar_lookup?title=Density-functional thermochemistry. III. The role of exact exchange&author=Becke,+D.&publication_year=1993&journal=J.+Chem.+Phys.&volume=98&pages=5648–5652" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B53-molecules-21-00185' class='html-xx' data-content='53.'>Lee, C.; Yang, W.; Parr, R.G. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. <span class='html-italic'>Phys. Rev. B</span> <b>1988</b>, <span class='html-italic'>37</span>, 785–789. [<a href="http://scholar.google.com/scholar_lookup?title=Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density&author=Lee,+C.&author=Yang,+W.&author=Parr,+R.G.&publication_year=1988&journal=Phys.+Rev.+B&volume=37&pages=785–789" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B54-molecules-21-00185' class='html-xx' data-content='54.'>Kohn, W.; Sham, L.J. Self-consistent equations including exchange and correlation effects. <span class='html-italic'>Phys. Rev. A</span> <b>1965</b>, <span class='html-italic'>140</span>, 1133–1138. [<a href="http://scholar.google.com/scholar_lookup?title=Self-consistent equations including exchange and correlation effects&author=Kohn,+W.&author=Sham,+L.J.&publication_year=1965&journal=Phys.+Rev.+A&volume=140&pages=1133–1138" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B55-molecules-21-00185' class='html-xx' data-content='55.'>Hehre, W.J.; Radom, L.; Schleyer, P.V.R.; Pople, J.A. <span class='html-italic'>Ab Initio Molecular Orbital Theory</span>; Wiley: New York, NY, USA, 1986. [<a href="http://scholar.google.com/scholar_lookup?title=Ab+Initio+Molecular+Orbital+Theory&author=Hehre,+W.J.&author=Radom,+L.&author=Schleyer,+P.V.R.&author=Pople,+J.A.&publication_year=1986" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B56-molecules-21-00185' class='html-xx' data-content='56.'>Cossi, M.; Rega, N.; Scalman, I.G.; Barone, V. Energies, structures, and electronic properties of molecules in solution with the C-PCM solvation model. <span class='html-italic'>J. Comp. Chem.</span> <b>2003</b>, <span class='html-italic'>24</span>, 669–681. [<a href="http://scholar.google.com/scholar_lookup?title=Energies, structures, and electronic properties of molecules in solution with the C-PCM solvation model&author=Cossi,+M.&author=Rega,+N.&author=Scalman,+I.G.&author=Barone,+V.&publication_year=2003&journal=J.+Comp.+Chem.&volume=24&pages=669–681&doi=10.1002/jcc.10189&pmid=12666158" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1002/jcc.10189" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/12666158" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li></ol></section><section class='html-fn_group'><ul><li><div class='html-p' style='text-indent:0em;'><span class='html-fn-content'><b>Sample Availability:</b> Samples of the compounds are not available.</span></div></li></ul></section>
    <section><p id="html-copyright">© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).</p></section>
  </div>
</article>
<style type="text/css">
  body{
    font-size: 11pt;
  }
</style>

</div>
<div class="clear"></div>
<div class="journal-info">
   <em><a href="/journal/molecules">Molecules</a></em>
   <span>EISSN 1420-3049</span>
   <span>Published by MDPI AG, Basel, Switzerland</span>
   <span><a href="/rss/journal/molecules">RSS</a></span>
   <span><a href="/journal/molecules/toc-alert">E-Mail Table of Contents Alert</a></span>
   </div>
                    </div>
                                        <div id="footer">
                        <ul>
                            <li><a href="/about/termsofuse">Terms &amp; Conditions</a></li>
                            <li><a href="/about/privacy">Privacy Policy</a></li>
                            <li><a href="/about/contact">Contact MDPI</a></li>
                            <li><a href="/about/jobs">Jobs at MDPI</a>
                        </ul>
                        <div id="copyright">&copy; 1996-2016 MDPI AG (Basel, Switzerland) unless otherwise stated</div>
                    </div>
                </div>
            </div>
        </div>
        
        <script src="http://img.mdpi.org/assets/js/first.js?06682939da1c3ece"></script>
        <script type="text/javascript">mdpiConfig('static_base_url', 'http://img.mdpi.org')</script>
        <script src="http://img.mdpi.org/assets/js/lib.js?e3cdff0ca6024bde"></script>
        <script src="http://img.mdpi.org/assets/js/main.js?a6d059ade3334abe"></script>
        <script>var banners_url = 'http://serve.mdpi.com';</script>
		<script type='text/javascript' src='http://img.mdpi.org/assets/js/serve-banner.js?2b7a1a93e8eb776c'></script>		
          <script src="http://img.mdpi.org/assets/js/article-html.js?951760f20a41de5e"></script>
  <script type="text/javascript">
    $('document').ready(function(){
      if(1 == 0){
        var doi = $('.html-art-header').find('a');
        var text = doi.text();
        doi.remove();
        $('.html-art-header p').append(text);
      }
      $('#maincol').css('position','static')
    });
  </script>


                  <script type="text/javascript">_uacct = "UA-5824718-2"; urchinTracker();</script>
            </body>
</html>
